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Equine grass sickness is a fatal dysautonomia. The aetiology of the disease is
unknown. It is characterised by severe neuronal degeneration and neuronal loss in
both the enteric and autonomic nervous systems. The current hypothesis is that
equine grass sickness is caused by a toxicoinfection with C. botulinum type C. This
study has investigated the isolation and characterisation of organisms resembling C.
botulinum type C from the gastrointestinal tract of horses with grass sickness and of
control horses and the detection of the botulinum type C neurotoxin (BoNT/C) in the
GI tract of horses by molecular methods.
No organisms typical of the Group III Clostridia were isolated from the GI tracts of
horses though organisms were isolated that were atypical with toxin gene profiles
that did not appear to match their phenotype. Five of the organisms isolated from the
GI tract of horses with equine grass sickness were found to produce detectable levels
of BoNT/C by ELISA. The BoNT/C gene was detected by PCR and Southern
blotting in four of the seven horses with equine grass sickness and none of the
control horses investigated. The BoNT/C gene was detected in several of the sites
sampled along the GI tract and was detected in the duodenum of all four horses.
These results support the hypothesis that a toxicoinfection with C. botulinum type C
is associated with equine grass sickness.
C. botulinum type C is one of the Group III Clostridia comprising C. botulinum types
C and D and C. novyi type A. These organisms are phenotypically similar and can
only be identified to species level on the basis of the major toxin they produce. The
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genes for these toxins are carried on pseudolysogenic phages and are readily lost.
The chromosomally encoded C2 toxin is the other major toxin produced by this
group though it was thought to be produced by the botulinum strains only.
Forty four strains identified as Group III Clostridia by phenotype were investigated
for the distribution of toxin genes by PCR to confirm the identities of these
organisms. Several combinations of the species-defining genes and the C2 genes
were found. The reference C. botulinum types C and D strains and one non-
neurotoxic strain of C. botulinum type C carried the genes for both components of
the C2 toxin. Of the 40 C. novyi type A strains, the gene for the alpha toxin was
found in 22 with 19 of these strains carrying the gene for one component of the C2
toxin. In the 18 alpha toxin-negative strains, 2 carried the genes for both components
of the C2 toxin and a further 11 strains carried the gene for the component I only.
The detection of the C2 toxin genes in strains identified as C. novyi type A is novel
and may suggest a role for one or both components of the C2 toxin in disease.
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The Clostridia comprise a group of gram positive, anaerobic spore forming bacilli.
They are pleomorphic both in colony type and cell type with some strains exhibiting
both swarming growth and discrete colonies on solid media. By microscopy they are
typically seen as large, straight rods with curved ends but may also appear as
elongated cells, filaments or club shaped cells. Clostridia show typical Gram positive
cell envelope morphology but may appear Gram variable and can appear Gram
negative, particularly in older cultures. All Clostridia produce spores that may be oval
or spherical and often distend the cells. Most species are obligate anaerobes though a
degree of oxygen tolerance is exhibited by some. Sporulation is not thought to occur
when the organisms are grown under aerobic conditions. They are ubiquitous in soil
and the environment and some are found as commensals of the human and animal
gut. The organisms may be saccharolytic and / or proteolytic. Clostridia
characteristically ferment carbohydrates and peptides for energy production and the
volatile and non-volatile fatty acids produced as the end product of this metabolic
activity can be used to identify Clostridia by gas liquid chromatography (GLC).
The species of Clostridia that are pathogenic for humans and other animals typically
produce one or more exotoxin.
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1.2 Clostridium botulinum
1.2.1 Phenotypic and genotypic groups of C. botulinum
The Clostridium botulinum species is a collection of organisms that vary
phenotypically and genotypically. They are classified as a single species on the basis
of their ability to produce neurotoxins with similar pharmacological actions. The
botulinum neurotoxin is one of the most potent naturally occurring neurotoxins.
C. botulinum has been divided into seven types, A to G, based on the antigenicity of
the neurotoxin produced.
C. botulinum has been grouped into four groups based upon phenotypic
characteristics. Group I contains Type A and proteolytic type B strains as well as the
non-neurotoxigenic C. sporogenes which is phenotypically related. Group II contains
non-proteolytic type B and type E strains and C. perfringens. Type C and D C.
botulinum and C. novyi comprise the Group III organisms and Group IV consists of
C. botulinum type G (though this has been renamed C. argentinense) and C.













I A, B, F + + + - A, iB, B, iV PP
II B, E, F - + + +/- A, B
III C, D +/- + + + A, P, B
IV G + - - - A, iB, B, iV PA
Table 1.1: Phenotypic characteristics of the four clostridial groups. Metabolic
end products are separated into volatile and non-volatile fatty acids. A,
acetic; P, proprionic; iB, isobutyric; B, butyric; iV, isovaleric; PP,
phenylproprionic; PA, phenylacetic.
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The nomenclature of C. botulinum strains based upon toxin production is not
straightforward. Though toxins A, B and E are chromosomally encoded and therefore
stable, there have been strains isolated that are capable of producing combinations of
two toxin types. Two strains were isolated from children with botulism that produced
90% type B toxin and 10% type F (Hatheway and McCroskey 1987) and a soil
isolate was found to produce 93% type A and 7% type F (Hatheway 1989). The
isolation of Clostridium barati that produces type F toxin (Hall et al. 1985) and
Clostridium butyricum that produces type E toxin (McCroskey et al. 1986) and have
been implicated in cases of botulism further complicates the classification of C.
botulinum.
Genetic studies based on 16S ribosomal RNA have demonstrated four distinct groups
that correlate with the groups based upon phenotypic characteristics (Hutson et al.
1993). Furthermore it has been demonstrated that all strains within Group I or Group
II are closely related though a degree of genetic diversity exists between the
organisms classed as Group III Clostridia (Lee and Riemann 1970; Nakamura et al.
1983).
The type C and D toxin genes are carried on bacteriophages in an unstable
association with the host cell and interconversion has been demonstrated within the
Group III Clostridia. Plasmids have been isolated from all groups of Clostridia and
include all toxin types (Strom et al. 1984). Multiple plasmids were found in types A
and B (Group I Clostridia) and in the Group III organisms C. botulinum type C and
type D. There is thought to have been lateral transfer of the BoNT genes between the
groups.
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It has been suggested that C. botulinum should be reclassified into four separate
species based upon the phenotypic and genotypic differences (Hutson et al. 1993).
1.2.2 The botulinum neurotoxins
Despite the antigenic differences between the botulinum neurotoxins they all have
similar pharmacological activities. They inhibit the release of neurotransmitter at
cholinergic synapses. The toxin is produced as a single chain molecule that is
cleaved by bacterial or host proteases to form the active bipartite toxin consisting of
a heavy chain (binding portion) covalently linked to the light chain (active
component) by a disulphide bond. The light chain component is a zinc-dependent
endopeptidase. The mechanism of action of the botulinum neurotoxins consists of
four stages; binding to the neuronal membrane, internalisation, membrane
translocation and enzymatic modification of the target in the cytosol (Montecucco et
al. 1994).
The structure of the botulinum neurotoxins
Botulinum neurotoxins are produced in the form of macromolecular complexes
termed progenitor toxins. These complexes range in size from 300-900kDa. The
larger complexes (with sedimentation rates 19S and 16S) may include a
haemagglutinin though the 19S form has only been associated with type A toxin. The
type C and type D toxins form both 12S and 16S complexes. The 12S complex
consists of the neurotoxin and a non-toxic non-haemagglutinin (NTNH) component.
The 16S complex consists of the neurotoxin, NTNH and a haemagglutinin
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component (HA) (Fujinaga et al. 1997). The progenitor toxin complex is thought to
be important for the oral toxicity of the derivative toxin providing protection from
proteases and acidity in the GI tract (Ohishi and Sakaguchi 1980).
The derivative toxin consists of a lOOkDa heavy chain and a 50kDa light chain. The
heavy chain is susceptible to the action of trypsin which cleaves it into two
fragments, Hc at the carboxy end appears to possess the binding site and HN at the
amino end remains linked to the light chain and is thought to be involved in
membrane translocation (Shone et al. 1985; Oguma et al. 1995).
Cell binding and internalisation
In order to bind to the pre-synaptic membrane at the neuromuscular junction the
botulinum neurotoxin must first diffuse into the circulation from the site of
production or adsorption. The most common route of entry is via the GI tract, either
from ingestion of pre-formed toxin or the localised production of toxin.
Binding studies have shown that the HA component of the 16S type C progenitor is
important in binding to glycoproteins and glycolipids in the small intestine in guinea
pigs. No binding activity was demonstrated in either the type C neurotoxin or NTNH
component. It is thought that this may account for the reduced oral toxicity of the
12S complex or purified neurotoxin alone. (Fujinaga et al. 1997). Both type C and D
toxins bind to sialoglycolipids and sialoglycoproteins but not to neutral glycolipids or
asialoglycoproteins (Inoue et al. 1999). The neurotoxin does not dissociate from the
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16S complex in the small intestine and the toxin therefore remains anchored to the
intestinal epithelium by the HA component (Fujinaga et al. 1997).
The botulinum neurotoxins are thought to cross the intestinal epithelium by
transcytosis (Maksymowych and Simpson 1998). Type A and B toxins were found to
be bound and transcytosed by human intestinal cells in a functionally active form.
Type C toxin does not appear to be efficiently transcytosed by human epithelial cells
which may explain why it is not associated with human disease though purified toxin
alone was used; it is not known if the 16S complex is able to bind to human cells
(Maksymowych and Simpson 1998).
The carboxy terminal of the heavy chain has been implicated in neurospecific
binding (Schiavo et al. 2000). This C terminal is composed of two distinct regions;
the amino terminal region is highly conserved between the botulinum neurotoxins.
The carboxy terminal region is poorly conserved and is required for binding of the
different types of toxins to separate receptors. A double receptor model for binding
of clostridial neurotoxins to neuronal cells has been proposed to account for the
actions of both polysialogangliosides and the glycoprotein receptor protein. The
polysialoglycoside binds all neurotoxins, acting as a trap for them and enabling the
small amounts of neurotoxin to cause disease. Bound toxin would then be able to
interact with the specific glycoprotein receptor that is responsible for the
neurospecificity of the toxins. Pre-incubation of botulinum neurotoxin with
gangliosides has been shown to inhibit binding to varying degrees depending on the
ganglioside. GTlb leads to a loss in toxicity of all toxin types (Kozaki et al. 1984).
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The specific receptors for the different toxin types are not known though binding of
BoNT/C is completely inhibited by pre-treatment of cells with neuraminidase,
pronase or trypsin indicating that a glycoprotein containing sialic acid may act as the
receptor (Yokosawa et al. 1989).
It has been proposed that internalisation of the neurotoxin is by receptor mediated
endocytosis via clathrin coated pits (Deinhardt et al. 2006). Once in the cell, the toxin
must be able to leave this compartment in order to reach the intracellular substrate. It
is thought that at low pH the toxins undergo conformational changes leading to the
exposure of hydrophobic segments enabling both the heavy and light chains to
penetrate the hydrocarbon core of the vesicle membrane. The neurotoxins have been
shown to form ion channels in planar lipid bilayers (Donovan and Middlebrook
1986).
Intracellular action
The botulinum neurotoxins are zinc-dependent metalloproteases. The Light chain
contains a highly conserved central region with a His-Glu-X-X-His motif which
forms the zinc binding region; zinc plays an important role in the hydrolysis of the
peptide bond (Schiavo et al. 1993). They cleave the proteins involved in
neuroexocytosis at a single specific site resulting in a sustained blockage of
neurotransmitter release (Table 1.2)
SNAP-25 and Syntaxin are bound to the pre-synaptic membrane and Synaptobrevin
(VAMP) is found on the vesicle membrane. These proteins form the SNARE (SNAP
receptor) complex required for neuroexocytosis. The SNARE proteins (VAMP and
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Syntaxin) promote membrane fusion and exocytosis together with the soluble factors
NSF (N-ethylmaleimide sensitive fusion protein) and a, P and y SNAPS (soluble
NSF attachment proteins). The pre-formed complex is highly stable and is resistant
to the action of the botulinum neurotoxins which prevent the formation of the
SNARE complex (Hayashi et al. 1994) (Fig 1.1).
The botulinum neurotoxins are thought to recognise their substrates by a two-step
process. It is thought that the initial recognition is by a nine amino acid SNARE
motif common to all three targets (Schiavo et al. 2000) and by recognition of the
specific peptide bond to be cleaved (Rossetto et al. 1994). This model accounts for
the observation that only one of many identical peptide bonds within the target
protein is cleaved and that short peptides containing the cleavage site are unaffected



















Figure 1.1: Schematic diagram of the SNAP/SNARE model of
neuroexocytosis showing the targets of the botulinum neurotoxins. (Adapted
from Oguma et al, 1995)
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Cytotoxicity of the type C neurotoxin
In addition to its ability to block neurotransmitter release the type C toxin has been
shown to be cytotoxic to murine spinal cord cells in vitro (Williamson et al. 1995)
and to rat hippocampal cells and cortical neurons (OsenSand et al. 1996). The
BoNT/C is the only neurotoxin capable of causing overt neuronal degeneration and
affects both mature and developing cells in vitro (Williamson and Neale 1998).
Neuronal cell damage was observed in primary neuronal cell cultures following 48h
incubation with BoNT/C with cells showing a loss of normal structures;
accumulation of degenerated mitochondria, dense membranous bodies and vesicles.
The neuronal somas were spherical and showed distorted nuclei and loss of Nissi
bodies (Kurokawa et al. 1987). These ultrastructural changes are similar to retrograde
degeneration of axons in vivo. In mature cells enlargement of the synaptic terminals
is seen shortly after exposure to BoNT/C followed by degeneration of axons,
dendrites and cell bodies (Williamson and Neale 1998).
The BoNT/C acts on syntaxin and is the only botulinum neurotoxin to do so. It is
thought that the neuronal cell death is mediated by the effects of BoNT/C on
syntaxin. It has been shown that syntaxin is required for neuronal cell development
and survival (Kurokawa et al. 1987; Williamson et al. 1995). Botulinum neurotoxins
can inhibit neurotransmitters other than acetylcholine in vitro due to the conservation
of the intracellular targets within neuronal synapses (Sugiyama 1980; Williamson
and Neale 1998). It is possible that BoNT/C is able to cause damage to a wide range
of neurons in vivo though it has not been shown to cause loss of motor neurons in
humans when used to treat dystonia (Eleopra et al. 1997).
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1.2.3 Toxins and disease
There are three forms of botulism: classical botulism caused by the ingestion of pre¬
formed toxin and two forms of toxicoinfectious botulism resulting from the
absorption of toxin produced in vivo. This toxin production may occur in the
intestinal tract following colonisation with C. botulinum or, more rarely, in a wound.
The main route of exposure to botulinum toxin is via the GI tract.
Types A, B, E and F botulinum are typically associated with human disease and
types C and D are thought only to affect animals (Rocke, 1993). There have been
reports of type C botulism in humans: two cases were reported in the USSR, one case
in France and one in the USA (Jensen and Price, 1987). BoNT/C has been shown to
be able to cleave recombinant human syntaxin and block the release of
neurotransmitter from isolated human neuromuscular junctions (Coffield et al. 1997).
It is therefore not known why C. botulinum type C rarely causes disease in humans
though it may be due to a lack of exposure to the toxin. It has been proposed that the
human GI tract lacks receptors for BoNT/C and therefore BoNT/C is unable to enter
the circulation (Maksymowych and Simpson 1998).
Botulism is also seen in most domestic animals and avian species. Outbreaks of
botulism occur most frequently in birds (Lamanna, 1987) and though birds are
susceptible to all types of botulinum toxin, type C toxin is responsible for the
majority of cases. Botulism has also been reported in a mink, ferrets, dogs, cats,
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horses, cattle and pigs. Horses are more susceptible to botulism than species such as
cattle, dogs and humans (Whitlock and Buckley 1997).
Foodborne botulism
Foodborne botulism is the most common form of the disease and is caused by the
ingestion of pre-formed toxin that has been produced in the food. Botulinum toxin
was first identified as the cause of disease in 1895 following an outbreak of botulism
caused by salt-cured ham (van Ermengen, 1897 cited in Hatheway, 1989). Botulism
in humans is rare and outbreaks are traditionally associated with consumption of
home-canned or bottled vegetables or meat (Macdonald et al. 1986). A recent
outbreak of botulism in Texas following a church supper was traced to a dish made
from frozen chillies that had not been stored adequately. It is more common in
Southern and Eastern Europe than in Northern and North-western Europe. Botulism
in animals is more common, possibly due to the consumption of rotting carcases and
other spoiled foodstuffs.
Rotting carcases of both vertebrates and invertebrates are a common source of
botulism for animals and birds. In particular, maggots have been shown to contain
high levels of BoNT/C (Haagsma, 1987) and provide a significant source of toxin for
birds (Mitchell and Rosendal, 1987). C. botulinum is thought to invade the tissues
from the gut following death. Mice were inoculated with type C spores immediately
prior to death, and the carcases incubated at 28°C. High levels of BoNT/C were
detected in these carcases for 28 days (Smith and Turner 1989).
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Landfill sites are also thought to be a source of botulism for herring gulls due in part
to their scavenging feeding habits. Spores of C. botulinum types B, C and D were
found in 63% of landfill sites (Ortiz and Smith 1994). The origin of the spores is not
known though carriage of C. botulinum spores has been documented in the
alimentary tracts of gulls.
Botulism in domestic animals is often referred to as forage poisoning and is
associated with the consumption of contaminated feed. Forage poisoning is usually
associated with type C botulinum in Northern Europe and type B in North America.
Toxicoinfectious botulism
The most common form of toxicoinfectious botulism is infant botulism, caused by
the production of toxin in the GI tract. Spores of C. botulinum colonise the immature
gut of children typically under 1 year old where they germinate and produce toxin.
The toxin is then absorbed through the gut wall and spreads systemically resulting in
a flaccid paralysis. Infant botulism is rare in many countries though it is now the
most common form of botulism in the US (Hatheway 1990). Honey contaminated
with spores of C. botulinum type B has been implicated in many cases of infant
botulism the US (Arnon 1980).
Intestinal colonisation with C. botulinum has been reported in adults but is extremely
rare and typically follows disruption to the GI flora following surgery or antibiotic
use (Chia et al. 1986). C. botulinum does not form part of the normal flora of the
human GI tract. Following intestinal colonisation of both adults and infants the
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presence of both the organism and toxin in the faeces has been demonstrated after
recovery from the disease (McCroskey and Hatheway 1988).
'Shaker foal syndrome' is usually caused by type B botulinum and affects foals
between 2 weeks and 8 months of age. It is thought that spores are ingested from the
soil and are able to colonise the immature gut. Toxin is produced in necrotic lesions
in the GI tract. Toxin is only detected in the faeces during the acute phase of the
disease. Toxicoinfectious botulism has not been documented in adult horses
(Whitlock and Buckley 1997).
Toxicoinfectious botulism caused by type C botulinum is seen in outbreaks of
botulism in broiler chickens and it is thought that the high-energy diet enhances both
the rate and amount of toxin production in the GI tract (Eklund et al, 1987).
Toxigenic and non-toxigenic strains of C. botulinum type C have been isolated from
poultry litter and this is thought to be a source of infection for the chickens (Eklund
et al, 1987). Poultry litter that is fed to cattle or used to fertilise fields has been
associated with botulism in cattle (McLoughlin et al. 1988; Ortolani et al. 1997).
Wound botulism
Wound botulism was first identified in 1943 with the isolation of C. botulinum type
A from the wound of a patient who had died of flaccid paralysis (Hatheway 1990).
Wound botulism is the least common form of botulism with only 16 cases reported
between 1967 and 1984 in the US and no cases reported to the Public Health
Laboratory Service of England and Wales prior to 1999. Wound botulism is
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increasing in the UK (England and Wales) with five cases reported in 2000, four in
2001, twenty in 2002, fifteen in 2003, forty in 2004, twenty-eight in 2005 and 17 in
2006 (http://www.hpa.org.uk7). All cases were associated with IV drug abuse and the
practise of skin or muscle popping. The clinical symptoms ofwound botulism are the
same as those seen in the classical form of the disease with neurotoxin produced in
the wound site entering the circulation.
1.3 Equine Grass Sickness (EGS)
Equine grass sickness is a largely fatal primary dysautonomia affecting horses and
other equids. Its aetiology is unknown. It was first recognised in 1909 in army horses
in Forfar, Scotland. The disease occurs mainly in the UK with a higher incidence in
Scotland (Milne et al. 1994) but has also been reported in Northern Europe,
Scandinavia (Gilmour 1987) and Australia (Stewart 1977). EGS is thought to be
identical to 'mal seco', a dysautonomia occurring in Argentina and Chile (Uzal and
Robles 1993).
1.3.1 Clinical signs
Equine grass sickness occurs in three forms, acute, subacute and chronic based upon
the severity of clinical signs and duration of symptoms (Doxey et al. 1991). Acute
grass sickness is the most severe form of the disease with a sudden onset of
symptoms and death or euthanasia occurring within 24 hours of the onset of
symptoms. Subacute grass sickness also has a rapid onset on symptoms though
horses may survive for up to seven days. Chronic grass sickness has a slower onset
of symptoms which can last for months before recovery of the horse or death.
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EGS is characterised by dysfunction of the gastrointestinal tract. Clinical signs range
from inability to swallow (dysphagia) and varying degrees of GI stasis. In the acute
from complete GI stasis with impaction of the colon and accumulation of fluid in the
small intestine may be seen. The clinical signs are thought to reflect the extent of
neuronal damage. The symptoms are less severe in subacute grass sickness with
reduced gut motility seen. The chronic form of the disease is characterised by a rapid
loss of weight and the development of a tucked up abdomen. Other symptoms
include a narrow base stance, muscle tremors, patchy sweating and ptosis (drooping
of the eyelid). There is no single pathognomonic sign for grass sickness and
diagnosis can only be confirmed by post-mortem detection of the neuronal
degeneration of peripheral autonomic ganglia (Doxey et al. 1995).
There is currently no treatment for acute and subacute grass sickness though some
chronic cases can recover with intensive nursing. These cases are typically those with
milder symptoms, in particular those involving dysphagia, loss of appetite, colic and
reduced gut motility (Milne et al. 1994).
Equine grass sickness is associated with severe neuronal degeneration and loss in the
autonomic and enteric nervous systems. Neuronal lesions were first observed in the
vertebral and prevertebral ganglia and the alimentary mural plexei (Obel, 1955).
Neuronal lesions have since been demonstrated in the central nervous system in the
brainstem nuclei, the dorsal root ganglia, the spinal cord, the intermediolateral
nucleus and the ventral horn (Barlow 1969; Gilmour 1973). Neuronal degeneration is
30
more widespread in the autonomic nervous system than in the central nervous
system. Enteric cholinergic neurons from the ileum of horses with grass sickness
showed altered cholinergic mechanisms and a reduction the release of acetylcholine
(Murray et al. 1994).
Neuronal degeneration is thought to be the primary event in grass sickness (Doxey et
al. 1995). The pattern of neuronal degeneration is indicative of a toxic cause. The
clinical severity of the disease reflects the extent of neuronal damage (Scholes et al.
1993). In acute grass sickness, neuronal degeneration is observed at most sites along
the GI tract whereas in chronic grass sickness it is restricted to the terminal small
intestine, in particular the ileum (Scholes et al. 1993; Doxey et al. 1995). It has been
hypothesised that equine grass sickness may be caused by a toxin that is either
ingested or produced within the GI tract (Doxey et al. 1995) and that the ileum is the
likely site of entry or toxin production given the extensive damage to the ileum
irrespective of the severity of disease (Scholes et al. 1993; Doxey et al. 1995). The
dosage of toxin and duration of exposure would therefore account for the differences
in the disease with acute cases exposed to large amounts of toxin along the length of
the GI tract over a short period of time. Chronic cases have less neuronal damage
which could be due to exposure to lower doses of the toxin in the distal ileum only
(Doxey et al. 1995). Damage to the peripheral autonomic nervous system could be
caused by toxin entering the circulation (Doxey et al. 1995) or by retrograde axonal
transport (Griffiths et al. 1994). Severe neuronal degeneration with little cell loss is a
characteristic of the acute form of the disease (Pogson et al. 1992) whereas horses
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with chronic grass sickness are typically found to have fewer damaged neurons but
show reduced counts of neurons (Pogson et al. 1992).
Epidemiology
Grass sickness, as the name suggests is associated with grazing. This was recognised
when the disease was first discovered (Tocher et al, 1923) and has been subsequently
confirmed in several epidemiological studies (Gilmour and Jolly 1974; Doxey et al.
1992; Wood et al. 1998). The disease shows a seasonal distribution with the majority
of cases in the UK occurring between April and July (Doxey et al. 1991). The disease
is more likely to occur on premises where grass sickness has previously occurred,
particularly in the last two years (Wood et al. 1998), horses that have recently moved
premises or to a different grazing area show an increased risk (McCarthy et al.
2004a). Young horses are more at risk then older animals with the peak age range for
disease being 1-7 years old (Gilmour and Jolly 1974). Prior contact of a horse with a
case of grass sickness has been associated with a reduction in the risk of disease
(Wood et al. 1998) though it is not known if this represents inherent resistance to the
disease or if non-fatal exposure to the disease confers resistance.
Aetiology
The epidemiology of the disease, in particular the seasonal distribution, difference in
susceptibility depending on age and the low incidence of the disease in horses with
prior contact with cases suggests an infectious aetiology with the causal agent related
to grazing.
32
Several factors have been suggested as putative aetiological agents including
poisonous plants, in particular white clover, fungi including Fusarium species and
oxidative stress in horses due to the consumption of plants under metabolic stress
(McGorum et al. 2000). There is little evidence to support these and many have been
discounted. A toxin producing bacterium seems to be the most likely cause.
In 1919 Clostridium botulinum was isolated from the stomach contents and intestine
from a horse with grass sickness (Tocher et al, 1923) and similarities between grass
sickness and classical botulism were noted and C. botulinum was considered to be
the cause of the disease. The organism was isolated from the spleens of horses with
subacute grass sickness and the isolated organism was said to reproduce the
symptoms of the disease in experimental animals (Tocher et al, 1923). The work of
Tocher was highly criticised and the theory was largely discounted. In particular the
protection study carried out by Tocher using a toxin/antitoxin mixture prepared from
known strains that reduced mortality in vaccinated animals to 2.8% compared to
9.3% in un-vaccinated controls (Tocher et al, 1923). This was criticised on the
grounds that human strains had been used for the preparation of the toxin/antitoxin
mixture and not those isolated from horses There was also criticism that the organism
isolated from horses had not been conclusively identified as Clostridium botulinum
or isolated in pure culture (Gaiger in Tocher et al, 1923). Gaiger, who had proposed
that grass sickness was cause by streptococci, was then appointed as the Chief
Investigator of the Animal Diseases Research Association and took on the
organisation of grass sickness research. The theory proposed by Tocher re-emerged
in 1994 when it was hypothesised that grass sickness is caused by a toxicoinfection
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with C. botulinum type C (J.K.Miller, pers. comm.). The BoNT/C has been detected
in 74% of acute cases, 67% of subacute and chronic cases and only 10% of control
cases from faecal or ileal samples (Hunter, 2000). Significantly lower levels of
antibodies (IgG) to the surface antigens of the closely related C. novyi type A and to
the BoNT/C were detected in horses with grass sickness compared to controls
(Hunter and Poxton 2001). Grass sickness has also been shown to be significantly
associated with low antibody levels to the surface antigens of C. novyi type A, C.
botulinum type C and BoNT/C in a matched case-control study (McCarthy et al.
2004b).
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1.4 Group III Clostridia
C. botulinum type C and D and C. novyi type A are grouped together on the basis of
their phenotypic and genotypic properties. C. novyi type A is a non-neurotoxigenic
variant of Group III botulinum. These organisms cannot be distinguished from each
other using traditional methods such as culture, biochemical properties or GLC
profiles. Their surface antigens are immunologically cross-reactive (Poxton 1984;
Poxton and Byrne 1984).
Group III organisms can only be identified to species level by the detection of the
major toxin produced; type C and D neurotoxin or the novyi alpha toxin. These
toxins are encoded on separate pseudolysogenic bacteriophages. The phage-host
relationship is unstable and the phages are readily lost. Cycles of phage loss and
reinfection are thought to occur in vivo (Eklund and Poysky, 1974). Repeated
subculturing and growth at 37°C can predispose to loss of the phage. Non-toxigenic
Group III organisms are indistinguishable from each other.
Sequence analysis of the 16S rRNA gene grouped C. botulinum type C and D and C.
novyi type A as a separate phylogenetic lineage (Hutson et al. 1993). There is
sequence diversity within this group however. There is 99% sequence homology
between type C and D botulinum which corresponds to 12 base mismatches and
seven unmatched bases over 1500 nucleotides (Hutson et al. 1993). The 1% sequence
divergence suggests that C. botulinum type C and D are separate species based on
genetic heterogeneity (Collins and East 1998). C. novyi shows 98% sequence
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similarity based on the 16S rRNA gene sequence (Hutson et al. 1993). The 2%
difference is also considered sufficient for C. novyi to be classed as a separate species.
C. novyi type A strains are commonly associated with wound and soft tissue
infections causing gas gangrene in humans. It was typically found in wounds
contaminated with soil e.g. war wounds. C. novyi infections had been extremely rare
until it re-emerged in 2000 as the cause of wound infection in injecting drug users
(IDUs).
1.4.1 Bacteriophages and Group III Clostridia
Bacteriophages have been found in Groups I, II, and III Clostridia, but have only been
associated with toxigenicity in the Group III Clostridia (Eklund et al, 1989).
Production of the major toxins is governed by the presence of the specific converting
bacteriophages (Eklund et al. 1971; Eklund et al. 1972; Eklund et al. 1976) Loss of
the bacteriophage is associated with a stable and permanent loss of toxicity. Non-
toxigenic isolates of toxigenic parent strains and isolates that had lost their
bacteriophage could be re-infected with the converting phage restoring toxigenicity
to the isolate.
The converting phages are thought to be pseudolysogenic due to the instability of the
host-phage relationship. Non-toxigenic isolates resembling C. botulinum have been
isolated from environmental samples and subculturing of toxigenic isolates leads to a
loss in toxigenicity (Eklund et al, 1987). This suggests that the phage is not stably
integrated into the host cell chromosome. Additionally, C. botulinum type C and D
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can be cured of their converting phages using both ultraviolet irradiation and acridine
orange (Eklund et al. 1971). Ultraviolet irradiation is a standard method of curing
cells of lysogenic bacteriophages and acridine orange is used to remove
extrachromosomal genetic elements from cells. The BoNT/C converting phage has
been shown to exist as a circular plasmid prophage in the lysogen rather than
integrating into the host chromosome (Sakaguchi et al. 2005). Subculture of
toxigenic isolates in the presence of phage-specific antiserum also results in loss of
the bacteriophage from the cell. Although this occurs spontaneously during sub¬
culture, a higher number of non-toxigenic isolates are found in the presence of anti-
phage serum (Oguma et al. 1976). This suggests that non-toxigenic strains can be re¬
infected by free phages in the culture medium.
Interconversion of C. botulinum type C and D
C. botulinum type C and D have been shown to be interconvertible by bacteriophages
(Eklund and Poysky 1974). Loss of the converting phage from the bacteria leads to
strains that can not be identified to species level. The non-toxigenic strains of C.
botulinum type C can be re-infected with the bacteriophage from a type D strain
resulting in the production of the type D neurotoxin. Similarly, non-toxigenic strains
of C. botulinum type D can be re-infected with the bacteriophage from a type C
strain resulting in the production of the type C neurotoxin.
The C2 toxin is a binary ADP-ribosylating toxin produced by the majority of type C
and some type D strains. It is chromosomally encoded and is produced during
sporulation (Nakamura et al. 1978).
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In non-C2 producing strains, type C strains that had been cured of their converting
phages could be infected by either the type C or type D phage but the type D strains
could only be re-infected with the homologous phage (Eklund and Poysky 1974).
Cultures infected with the type C phage were immune to infection with the type D
phage and vice versa suggesting that the phages are antigenically related (Eklund et
al, 1974).
It has been suggested that interconversion between type C and D can occur in nature
as a result of the pseudolysogenic nature of the bacteriophages and that types C and
D can arise from a common non-toxigenic strain. The genetic variation based on 16S
rRNA sequence that suggests these organisms are separate species was based on
comparison between one type C and one type D strain. Genetic heterogeneity has
been demonstrated within C. botulinum type C strains (Nakamura et al. 1983).
Interconversion between C. botulinum and C. novyi
Loss of the phages carrying the type C and D neurotoxins and the novyi alpha toxin
leads to isolates that are indistinguishable. Interspecies conversion between C. novyi
and C. botulinnm by infection with the relevant converting phage has been
demonstrated (Eklund and Poysky 1974; Eklund et al. 1974). A non-toxigenic strain
derived from C. botulinum type C cured of the type C phage could be infected with
the phage from a C. novyi isolates resulting in the production of the novyi alpha toxin.
Isolates infected with either the type C or type D phage are immune to infection with
the type C and D phages but remain sensitive to infection with the novyi phage. Both
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phages were shown to be carried through the spore state though one of the phages
was frequently lost upon subculture (Eklund et al, 1987).
Antigenicity and stability of the bacteriophages
The type C and D phages are thought to form a phage family (Sunagawa and Inoue
1992). They share similar biological and biophysical properties and have a close
DNA homology. They have also been divided into four groups based on the
antigenicity of the phage and the spectrum of host cells they infect (Sunagawa and
Inoue 1991). Conversion of a cell to toxicity only occurs with specific phages and
bacterial cells. Phages have been isolated from C. botulinum type C and D and C.
novyi type A that do not convert non-toxigenic isolates to toxin production
(Sunagawa and Inoue 1991; Eklund et al, 1987). The non-converting phages are
identical in their antigenicity and host specificity though they are smaller than the
converting phages (Sunagawa and Inoue 1991).
Bacterial strains may differ in the stability of toxin production due to instabilities of
the pseudolysogenic phages. Loss of toxigenicity occurs at different rates depending
on the combination of phage and host (Oguma et al. 1976). Toxigenicity may also
vary with the passage history of the phage in the laboratory. The converting ability of
phages has been shown to decrease following repeated propagation through a
bacterial strain (Oguma and Iida 1979). Incubation at 37°C was shown to select
virulent mutants of the converting phages that were unable to pseudolysogenise the
bacterial host and instead induced lysis of the host cell (Eklund et al, 1987).
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The stability of the phage-host relationship may be influenced by environmental
conditions. This is thought to affect the epidemiology of disease such as avian
botulism cause by type C botulinum (Hariharan and Mitchell 1976). Avian botulism
outbreaks are rare in areas with high alkalinity and are commonly seen in areas of
moderate to low alkalinity such as marshlands (Eklund et al, 1987). High salt
concentrations have been shown to inhibit the growth of C. botulinum type C
(Eklund et al, 1987) whereas low salt concentrations increase both the rate of
infection with the type C phage and the stability of the host-phage relationship
(Eklund and Poysky 1974). This may account for the high incidence of C. botulinum
type C at the periphery of salt flats and the association of these areas with avian
botulism (Eklund et al, 1987).
1.4.2 Toxin production by Group III Clostridia
Toxins produced by C. botulinum types C and D
C. botulinum type C and D are capable of producing up to three toxins. The defining
neurotoxin, the C2 toxin (a binary ADP-ribosylating toxin) and the C3 toxin, an
exoenzyme also associated with ADP-ribosylation. The C3 toxin is encoded on the
converting phage with the BoNT/C or BoNT/D.
The C2 toxin is located on the bacterial chromosome. It is produced during
sporulation only, with higher levels found in cultures producing high numbers of
spores (Nakamura et al. 1978). It is thought that the C2 toxin may form part of the
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spore coat as a structural protein (Yamakawa et al. 1983). It is produced by the
majority of type C and some type D strains.
The type C and type D neurotoxins are closely related with 52.2 % sequence identity
(Sunagawa et al. 1992). The toxins have common antigenic sites as well as antigen
sites specific to the toxin type. Heterogeneity is seen in the type C and type D
neurotoxins and is thought to be a result of mutation or recombination of the phage
genome during the cycles of loss and re-infection with bacteriophages that occur
naturally (Sunagawa and Inoue 1991).
The C3 exoenzyme has been divided into two groups on the basis of its antigenicity
(Moriishi et al. 1993). It is thought that the 21.5kbp DNA fragment encoding the C3
exoenzyme may be a mobile genetic element (Hauser et al. 1995) due to its
similarities with the site-specific transposon family Tn554.
Toxins produced by C. novyi type A.
C. novyi type A produces the species-defining novyi alpha toxin. The alpha toxin is
one of a family of large clostridial cytotoxins. It is a lethal necrotising toxin in vivo
causing oedema. The alpha toxin modifies GTP-binding proteins in vitro and is a
potent cytotoxin. C. novyi type A also produces the gamma toxin, delta and epsilon
toxins. The gamma toxin is a phospholipase C. The delta toxin is an oxygen-labile
haemolysin and the epsilon toxin is a lipase. These toxins are responsible for the
cultural characteristics of the organism; the gamma toxin produces lecithinase
reaction observed in the culture of the organism on egg yolk agar and the epsilon
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toxin is responsible for the 'pearly layer' associated with growth on egg yolk agar.
The delta toxin gives the haemolysis associated with growth of the organism on
blood agar.
1.4.3 Toxins that affect the cytoskeleton
The C. novyi alpha toxin, C2 toxin and C3 exoenzyme all affect the cytoskeleton
causing a characteristic 'rounding up' of cells in vitro.
C. novyi alpha toxin
The C. novyi alpha toxin is one of a family of large clostridial cytotoxins including
Clostridium difficile toxins A and B and the lethal toxin from Clostridium sordelli.
These toxins are high molecular weigh (250-300kDa) molecules that glycosylate the
low molecular weight GTP proteins of the Rho family (Busch and Aktories, 2000).
The novyi alpha toxin is thought to consist of three functional domains: The N-
terminal catalytic region, a central hydrophobic region involved in membrane
translocation and a C-terminal binding region (vonEichelStreiber et al. 1996).
Cell binding and internalisation
Clostridial repetitive oligopeptides (CROPs) have been identified in the C-terminal
region of the large clostridial cytotoxins (Hofmann et al. 1995). These consist of 25-
30 amino acids repeated 14-30 times which function as ligands. They form
multivalent receptor binding domains which enable multiple interactions with a
receptor (vonEichelStreiber et al. 1996). The receptor for the novyi alpha toxin is
unknown though it is thought to act ubiquitously against mammalian cells (Ball et al.
1993) suggesting the presence of a ubiquitous receptor.
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The novyi alpha toxin is taken up into cells by receptor-mediated endocytosis.
Acidification of the endosome is thought to induce a conformational change in the
protein allowing entry into the cytosol (Ball et al. 1993). Translocation into the
cytosol is thought to involve the insertion of the central hydrophobic region of the
toxin into the endosomal membrane (vonEichelStreiber et al. 1996).
Intracellular action
The novyi alpha toxin acts on the proteins Rho, Rac and Cdc42 (Selzer et al. 1996)
modifying them in their effector regions. The Rho-GTPases regulate the actin
cytoskeleton and have a role in signal transduction (Hall 1998; Bishop and Hall
2000). The primary function of the Rho family is the regulation of the organisation of
the actin cytoskeleton. Rho is involved in the formation of stress fibres, Rac is
involved in the formation of membrane ruffles, lamellipodia and focal contacts and
Cdc42 is involved in the formation of filopodia. Rho proteins also have a role in
signal transduction cascades acting as molecular switches through nucleotide
exchange in the GTPase cycle (Bishop and Hall 2000).
This cycle is tightly regulated. In its inactive form Rho is found bound to GDP in the
cytosol. This inactive form is maintained by binding to guanidine nucleotide
dissociation inhibitors (GDI). Rho is activated by GDP-GTP exchange mediated by
guanidine nucleotide exchange factors (GEFs). Binding of GTP enables protein
interaction with effector molecules. Hydrolysis of GTP to GDP by GTPase-
activating proteins (GAPs) returns Rho to its inactive state.
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The novyi alpha toxin modifies Rho at a specific amino acid (threonine 37) and Ras
and Cdc42 at the homologous threonine 35 when Rho is in its inactive, GDP bound
form (Selzer et al. 1996). This threonine residue is highly conserved and is involved
in the binding of GDP/GTP to the Rho proteins. The alpha toxin acts as a catalyst in
the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to Thr 37/35.
The novyi alpha toxin is the only large clostridial toxin to use UDP-N-
acetylglucosamine as a substrate rather then UDP-glucose (Busch et al. 2000). The
glycosylation of Rho blocks the coupling of Rho proteins with their effector
molecules and inhibits nucleotide exchange and membrane cycling (Sehr et al. 1998;
Busch and Aktories 2000).
C2 toxin
The C2 toxin belongs to a class of actin-specific ADP-ribosyltransferases that
includes the Clostridium perfringens iota toxin and the Clostridium difficile ADP-
ribosylating toxin. The C2 toxin is a binary toxin composed of two separate
components C2CI and C2CII (Aktories et al, 1992). Both components are required
for toxicity. C2CI is the enzymatic component and C2CII is responsible for binding
activity.
Cell binding and internalisation
The N-terminal region of C2CII is cleaved by trypsin to give an active form of the
protein that forms oligomers, predominantly heptamers (Barth et al. 2000). The C-
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terminal region is involved in binding to the cell surface (Blocker et al. 2000).
Binding of C2C1I was blocked by the use of an antibody against the C-terminal
region and by truncation of this region. It is thought that the receptor binding site
may be stabilised by the seven terminal amino acid residues as deletion of these also
blocks binding (Blocker et al. 2000).
Activated C2C1I binds to asparagine-linked complex carbohydrates (Eckhardt et al.
2000). This was determined using a C2 resistant cell line that was found to be
deficient in N-acetylglucosaminyltransferase I. These cells were unable to make N-
linked complex carbohydrates. Restoration of N-acetylglucosaminyltransferase I by
gene transfection restored sensitivity to the C2 toxin (Eckhardt et al. 2000). There are
no sequence similarities in the C-terminal region of the C2 toxin and other ADP-
ribosylating toxins suggesting that the toxins act through different receptors. There is
evidence that the C2 toxin acts through a carbohydrate receptor alone as no naturally
resistant cell line has been found suggesting that the receptor is ubiquitous on
mammalian cells (Eckhardt et al. 2000).
The N-terminal region of the C2CI component is involved in the interaction of the
two components. The docking site is formed after binding of the C2CII component to
the cell surface (Barth et al. 1998). The C2 toxin then enters cells by receptor
mediated endocytosis (Simpson, 1989). Acidification of the endosomal compartment
is required for entry into the cytosol (Barth et al. 2000). The C2CII has the ability to
form ion channels in artificial lipid bilayers (Schmid et al. 1994) and it is thought
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that following acidification of the endosome, oligomeric C2CII forms a channel in
the membrane through which C2CI enters the cytosol (Barth et al. 2000).
Intracellular action
The C2CI component mono-ADP-ribosylates G actin at arginine 177 resulting in
inhibition of actin polymerisation (Aktories et al. 1986). Actin forms an essential
component of the cytoskeleton and is involved in motile processes such as migration,
phagocytosis, secretion and intracellular transport based on its ability to polymerise
and form microfilaments (Aktories and Wegner 1992). Actin exists in equilibrium
between two forms; the filamentous F-actin and monomeric globular G-actin
(Aktories and Wegner 1992). The ADP-ribosylated G-actin acts as a capping protein
at the end of actin filaments preventing further polymerisation. Depolymerisation
occurs at the opposite end.
The catalytic site is found at the C-terminal region with conserved glutamic acid
residues at positions 387 and 389, serine-348 and arginine-299 essential for ADP-
ribosyltransferase activity (Barth et al. 1998). A highly conserved catalytic glutamate
residue is found in other ADP-ribosyltransferases (Barth et al. 1998). Serine-348 is
thought to be involved in either NAD binding or as a catalyst and arginine-299 is
thought to be involved in NAD binding or stabilising the active site.
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1.4.4 Toxins and disease
C. novyi alpha toxin
The novyi alpha toxin is associated with soft tissue wounds in man and animals
classically causing gas gangrene in war wounds. Gas gangrene is an invasive
infection of the muscles characterised by toxaemia, localised oedema, tissue death
and a variable degree of gas production (Maclennan 1962). Gas gangrene is
associated with a variety of pathogenic Clostridia and approximately one third of
cases are associated with C. novyi type A (Smith, 1975). Wound infections involving
C. novyi type A are associated with high levels of mortality due to the lethal
necrotising properties of the alpha toxin.
C. novyi wound infections were considered rare until an outbreak of C. novyi wound
infection among IDUs in 2000. Between April and August 2000, 60 IDUs in
Scotland presented with severe skin and muscle damage with swelling at an
intramuscular injection site with 23 patients dying of systemic shock. Cases were
categorised as definite where both injection site inflammation and multi-system
failure were seen and probable if either injection site inflammation or multi-system
failure were seen. C. novyi was isolated from a total of 13 cases, 8 from definite
cases and 5 from probable cases (McGuigan et al. 2002). C. novyi was the most
frequently isolated pathogen and the clinical findings are consistent with the
pathogenesis of C. novyi. The majority of cases had injected heroin extravascularly
(muscle- or skin- popping). The source of the infection appeared to be a batch of
heroin contaminated with spores of C. novyi type A. The heroin is thought to have
been purer than normal (60-80% purity rather than the normal 30-40%) requiring the
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addition of more citric acid in order to dissolve it for injection (McGuigan et al.
2002). The acidic solution is thought to have devitalised the soft tissue forming the
site for growth and toxin production by C. novyi. Epidemiological studies revealed
temporally related cases in England and the Republic of Ireland.
Amplified fragment length polymorphism (AFLP) analysis of C. novyi isolates
obtained from the 2000 outbreak found the isolates from IDUs to be similar
suggesting a common source (McLauchlin et al. 2002).
C2 toxin
The C2 toxin is able to cause morbidity and mortality in experimental animals
though its role in natural infection is poorly understood. The C2 toxin can cause an
increase in vascular permeability and fluid accumulation in intestinal loops (Ohishi
1983). Damage to the epithelial surface of the intestine is also seen (Ohishi and
Odagiri 1984). The C2 toxin can also cause hypotension, haemorrhaging and a
collection of fluid in the thoracic cavity in experimental animals (Simpson 1982).
The C2 toxin may have an effect on the immune system. It has been shown to inhibit
neutrophil migration (Aktories et al, 1992) and to enhance granule protein release
and the production of oxygen free radicals in neutrophils (Norgauer et al. 1988) and
to inhibit histamine release from mast cells (Aktories and Wegner, 1989).
The C2 toxin has been implicated in disease in some cases of type C botulism in
broiler chickens involving diarrhoea and enteritis in addition to the neurological
symptoms (Ohishi and DasGupta, 1987). The C2 toxin has also been isolated from an
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outbreak of botulism in horses in North America associated with the consumption of
processed alfalfa hay cubes (Kinde et al. 1991). Intramuscular oedema was observed
in five of the horses involved in the outbreak and suggests the possible involvement
of the C2 toxin.
1.5 Clostridium tetani
C. tetani is a strict anaerobe. Most strains are motile by peritrichous flagella and
exhibit a fine swarming growth an agar. Discrete colonies may be seen on media
containing 3-4% agar. Colonies are flat and translucent showing a zone of beta-
haemolysis. Spores are typically round and terminal. Their diameter can be up to
twice that of the vegetative cell giving the characteristic 'drumstick' appearance.
1.5.1 Tetanus toxin
Tetanus toxin is produced as a single polypeptide chain of approximately 150kDa
(Bizzini 1979). The molecule is subsequently cleaved into two fragments by
proteases produced by the bacteria (Helting et al. 1979), a lOOkDa heavy chain and a
50kDa light chain that are linked by a disulphide bond. Treatment of the bichain with
papain cleaves the heavy chain resulting in two fragments; fragment B, a bichain
molecule of 95kDa and fragment C, a 45Kda molecule derived from the heavy chain
(Helting et al. 1979). These fragments are non-toxic.
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The binding site is found on the heavy chain in the fragment C region and the high
affinity of the toxin molecule and the fragment C portion for gangliosides suggests
that the membrane receptors contain ganglioside structures (Morris et al. 1980). It
has been proposed that a second, protein, receptor may also be involved in the
binding of tetanus toxin (Montecucco 1986).
Tetanus toxin acts in the same way as the botulinum neurotoxins. It is a zinc
dependent endopeptidase and cleaves VAMP. Tetanus toxin inhibits exocytosis in
inhibitory neurons preventing the release of the inhibitory neuromuscular
transmitters gamma-aminobutyric acid and glycine whereas the botulinum
neurotoxins block neurotransmitter release at the neuromuscular junction. Though
the mechanisms of action of the toxins are identical at the cellular level the
differences in the site of action accounts for the differing symptoms with tetanus
causing the characteristic spastic paralysis of the voluntary muscles and botulism
resulting in a flaccid paralysis.
1.5.2 Tetanus toxin in disease
Classical tetanus was first described in ancient times and was first confirmed as a
transmissible disease in 1884 (Hatheway 1990). The disease results from spores of C.
tetani entering a wound. If the redox potential is low enough the spores germinate
and growth of the organism occurs. This is typically seen in deep puncture wounds
contaminated with soil. C. tetani is found in the GI tracts of many animals and is
ubiquitous in soils. The tetanus toxin is produced in the wound and enters the system
by either diffusion into surrounding muscle, by transport through the lymphatic
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system or by passage through the nerve cells. The toxin passes through the nerve
axons by retrograde transport to the central nervous system.
Clinical symptoms usually appear between 7 and 10 days after the wound becomes
infected though they can appear between 3 and 30 days. Initial symptoms often
include pain and stiffness, particularly around the wound site and trismus - where the
muscles of the jaw are affected. Symptoms become generalised. Tetanus may be
mild, with good response to treatment and low mortality, severe with 20-40% fatality
or very severe with a 50-90% mortality rate. Tetanus is rare in the developed world
due to an effective toxoid vaccine. Neonatal tetanus is still prevalent in some areas of
the world with an estimated 400, 000 cases per year and is due to infection of the
umbilicus, often associated with unusual anointing practices.
1.5.3 Neonatal tetanus and St Kilda
The Islands of St. Kilda form the most remote part of the British Isles and lie 110
miles west of mainland Scotland. The one inhabited island was largely self-sufficient
with an economy based on seabirds. On 29th August, 1930 the Island was evacuated
largely due to the decline in the population. Neonatal tetanus was common on St
Kilda in the latter part of the 19th Century. It was referred to by the Islanders as 'the
sickness of eight days'. Between 1855 and 1876 there were 56 births on the Island
with 41 of the babies dying from neonatal tetanus. The source of this is unknown;
there was a midwife on the island but midwifery procedures were highly secretive. It
is thought that umbilicus was anointed with fulmar oil and this was the source of the
infection (Woody and Ross 1989). Fulmars produce thick, orange/red oil as a by-
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product of their diet of fish and are able to 'spit' this oil 2-3 feet as a defence against
predators. The oil was collected by the St Kildans and stored in the dried stomach of
a gannet. The living conditions of the St Kildans may also have had an impact with
the Islanders sharing their homes with their cattle in winter allowing the dung
produced to dry on the floor of the crofts. The introduction of public health nursing
methods improved the situation on the Island with no cases of neonatal tetanus
reported after 1891 (Woody and Ross 1989).
Aims of Thesis
It has been proposed that C. botulinum type C is either carried in the GI tract or is
ingested and that an unknown trigger allows the germination of spores and toxin
production within the GI tract. To investigate the hypothesis that equine grass
sickness is caused by a toxicoinfection with C. botulinum type C, the aims of this
thesis were:
• To isolate Group III Clostridia from the contents of the gastrointestinal tract
of horses with equine grass sickness and from control horses and to compare
these isolates using phenotypic and genotypic methods.
• To detect BoNT/C producing organisms in the GI tract of horses with and
without grass sickness to further investigate the link between a
toxicoinfection with C. botulinum type C and equine grass sickness
independent of the need to culture viable organisms.
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• To develop methods for the characterisation of Group III Clostridia from a
variety of sources, to identify strains that have lost their defining toxin gene
and to identify any strain types that are specifically associated with equine
grass sickness
• To isolate C. tetani and detect the tetanus neurotoxin gene from




2.1 Isolation and identification of Group III Clostridia
Group III Clostridia comprise C. botulinum types C and D and the closely related C.
novyi type A.
2.1.1 Bacterial strains
Bacterial strains of Group III organisms (C. botulinum type C and D and C. novyi
type A) C. botulinum types A, B and E and of other Clostridia were obtained from the
Microbial Pathogenicity Research Laboratory (MPRL) collection (Centre for
Infectious Diseases, University of Edinburgh College of Medicine and Veterinary
Medicine, The Chancellor's Building, 49 Little France Crescent, Edinburgh, UK),
the National Culture of Type Strains (NCTC, Central Public Health Laboratory,
London, UK), the National Collection of Industrial Bacteria (NOB, Aberdeen,
Scotland) and from the Royal Infirmary ofEdinburgh (RIE, Edinburgh) (Table 2.1).
54
Lab ID Organism Source
2509 C. botulinuin type A Source unknown
2511 C. botulinum type B NCTC 3732
2512 C. botulinum type E NCTC 8266
2591 C. sporogenes Source unknown
2528 C. irregularis NCIB 11830
2618 C. butyricum Source unknown
2645 C. sordelli NCTC 6801
2651 C. sphenoides NCTC 507
2656 C. sardiniensis Isolate obtained from RIE
2661 C. perfringens NCTC 8257
2713 C. perfringens NCTC 6121
2778 C. tetani NCTC 5413
3209 C. novyi type A RIE 2628
3271 C. barati RIE 2826
3573 C. tertium RIE 4895
3923 C. botulinum type D NCTC 8265
4354 C. difficile RIE 12771
4526 C. difficile Isolate obtained from RIE
4564 C. botulinum type C NCTC 8548
Table 2.1: Bacterial strains used as positive controls for PCR reactions and
in Heteroduplex mobility assays.
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2.1.2 Samples
Samples used consisted of tonsillar tissue, gastric contents, duodenal tissue and
contents, jejunal tissue and contents, colon tissue and contents, rectal tissue and
contents, liver and spleen. They were collected from 7 euthanased cases of acute
grass sickness. Samples were collected immediately post-mortem from
histopathologically confirmed cases. Comparable samples were collected from 5
horses euthanased for non-GI related causes.
2.1.3 Isolation of Group III organisms
Approximately lg of each specimen was added to 5ml pre-reduced modified Brain-
Heart infusion broth. This comprises 37g/L Brain-heart infusion broth (Oxoid,
Basingstoke, UK), lOg/L Yeast Extract (Difco), lg/L L-cysteine-HCl, lOml/L
gentamicin (lmg/ml base, aqueous solution) and cooked meat particles. The samples
were incubated anaerobically at 30°C in a DWS Mark III anaerobic work station
(Don Whitley Scientific, Shipley, UK). Serial dilutions were plated out after 24h, 2
days and 4 days incubation onto EGS agar comprising lOg/L Trypticase (Becton,
Dickson & Company, Sparks, MD), lOg/L Proteose Peptone (Oxoid, Basingstoke,
UK), 5g/L Yeast Extract (Difco), 5g/L NaCl, 2.5g/L Sodium succinate and 20g/L
Agar (Oxoid, Basingstoke, UK) with the further addition of 0.75g/L L-cysteine HC1,
lOmg/L gentamicin, lOOml/L egg yolk emulsion (Oxoid, Basingstoke, UK) and
50ml/L Horse serum (Oxoid, Basingstoke, UK). Plates were checked for the
presence of lipase- and lecithinase- positive colonies at 24h intervals. Lipase and
lecithinase positive colonies were isolated by sub-culturing onto fresh EGS agar
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plates and finally into cooked meat broth to be kept as stock cultures. Colonies
positive for lipase only or lecithinase only were also isolated in the same way.
2.1.4 Identification of Group III organisms
Group III organism were identified by their biochemical properties (lecithinase and
lipase production), morphology when examined by phase contrast microscopy and
Gram stain by light microscopy (Gram positive rods with subterminal oval spores),
and gas liquid chromatography profiles (Brown et al, 1996).
2.1.5 Culture of isolates for DNA extraction
Each isolate and reference strain was inoculated into pre-reduced AIM-CMB (Brown
et al, 1996) and incubated overnight at 30°C before plating onto Fastidious Anaerobe
Agar (Lab M, Bury, UK) supplemented with 10% egg yolk emulsion (Oxoid,
Basingstoke, UK). Plates were incubated for up to four days and checked at 24h
intervals.
2.1.6 Extraction of DNA for PCR
DNA was extracted from plated colonies using Chelex 100 chelating resin (Bio-Rad,
Richmond, CA) according to the method of de Lamballerie et al (1992).
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2.1.7 PCR detection of 16S rRNA and clostridial toxin genes
PCR detection of the 16S rRNA gene was used to confirm the presence of bacterial
DNA in the samples. The primers used to detect specific toxin genes were chosen
from published sequences; the PCR reaction and cycling conditions used were as
published for use with those primers. The primer sequences are given in Table 2.2,
Reaction conditions are given in Table 2.3 and cycling conditions are given in Table
2.4. All primers were supplied by MWG Biotech. (MWG Biotech AG, Ebersberg,
Germany). A Techne TC-412 thermal cycler was used for all PCR reactions. In all
PCR reactions the relevant reference strains that were known to contain the particular
gene were used as positive controls. A negative control using purified water in place
of the template DNA was included in each PCR reaction.
2.1.8 Visualisation of PCR products
PCR products (10 pi) were run on 1% agarose gels (BoNT/C, BoNT/D, novyi a
toxin, C2CI and C2CII genes) or 1.5% agarose gels in TAE buffer (40mM Tris and
2mM disodium EDTA, pH8.0) containing ethidium bromide (O.lmg/ml). Products
were visualised under ultraviolet light. The readyload lOObp DNA ladder
(Invitrogen) was used as a molecular weight marker to size products.
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Gene Primer Primer sequence Reference
16s rRNA 16SF 5 '-GAACGCGAAGAACCTTAC-3' (Nubel et al. 1996)
16SR 5 '-TAGCGATTCCGACTTCA-3'
BoNT/C Tox384 5 '-AAACCTCCTCGAGTTACAAGCCC-3' (Williamson et al. 1999)
(nested) Tox625 5' -CTAGACAAGGTAACAACTGGGTTA-3'
Tox850* 5' -GAAAATCTACCCTCTCCTACATCA-3'
Toxl049* 5AATAAGGTCTATAGTTGGACCTCC-3'
C2CI C2CIF 5AAGGAAGATAAAACAAAAAT-3' (Fujii et al. 1996)
C2CIR 5 '-CCTAATGATACAAATGAAAA-3'
C2CII C2CIIF 5'GCAGAAGTTTCAGGTAGTTTACAAC-3' (Kimuraetal. 1998)
C2CIIR 5' -CGCATTCTATAACGACCTTCTGGA-3'
BoNT/D BoNT/D-F 5' -GTGATCCTGTTAATGACAATG-3' (Sunagawa et al. 1992)
BoNT/D-R 5 '-TCCTTGCAATGTAAGGGATGC-3'
A, B&E BoNT/A-F 5 '-AGCTACGGAGGCAGCTATGTT-3' (Lindstrom et al. 2001)





C. novyi Nov-F 5 '-GGTGCGATTCAAGAGGCCACA-3' (Hofmann et al. 1995)
alpha toxin Nov-R 5 '-CGCTCCTAGCAGTCCCGAAAT-3'
C. perfringens PA-F 5 '-GCTAATGTTACTGCCGTTGA-3' Songer & Bueschel,
alpha toxin PA-R 5 '-CCTTCTGATACATCGTGTAAG-3' 1999
C. perfringens PB-F 5'-GCGAATATGCTGAATCATCTA-3' Songer & Bueschel,
beta toxin PB-R 5' -GCAGGAACATTACTATATCTTC-3' 1999
C. perfringens PE-F 5 '-GGAGATGGTTGGATATTAGG-3' Songer & Bueschel,
enterotoxin PE-R 5' -GGACCAGCAGTTGTAGATA-3' 1999
Table 2.2: Primer sequences for amplification of target genes.
* denoted the reverse primers for the nested PCR.
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C. novyi alpha toxin
IX (50mM KC1,
lOmM Tris-HCl)
1.5mM 12.5mM 10pmol.pl 2.5U
BoNT/C IX (50mM KC1,
lOmM Tris-HCl)
3.75mM 0.2mM lpM 1.25U
A, B &E multiplex IX (50mM KC1,
lOmM Tris-HCl)





2.0mM 0.12mM lOpmol/pl 5U
Table 2.3: Reaction conditions for PCR using primer pairs detailed in Table
2.2. All reactions were carried out in a total volume of 100pl with 5pl of









16s rRNA 5 min at 94°C 35 1 min at 94°C
1 min at 63°C
1 min at 72°C
5 min at 72°C
BoNT/C 5 min at 80°C 30 1 min at 95 °C
1 min at 55°C
1 min at 72°C
10 min at 72°C
C2CI 3 min at 94°C 35 45s at 94°C
2 min at 45 °C
1 min at 72°C
5 min at 72 °C
C2CII 3 min at 94°C 40 45s at 94°C
1 min at 53°C
3 min at 72°C
5 min at 72°C
BoNT/D 10 min at 95 °C 25 1 min at 94°C
1 min at 55°C
1 min at 72°C
3 min at 72°C
A, B&E 3 min at 94°C 28 30s at 95°C 3 min at 72°C
multiplex 25s at 60°C
1 min 25s at 72°C
C. novyi alpha 3 min at 94°C 30 1 min at 95°C 5 min at 72°C
toxin 1 min at 48°C
1 min at 72°C
C. perfringens 5 min at 94°C 35 1 min at 94°C 5 min at 72°C
alpha, beta and 1 min at 50°C
enterotoxins 1 min at 72°C
Table 2.4: Cycling conditions for PCR reactions using primer pairs detailed in
Table 2.2.
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2.1.9 Immunomagnetic separation (IMS) of Group III Clostridia
Coating of magnetic beads
Aliquots (33 pi) of Dynal magnetic beads coated in anti-rabbit immunoglobulin
(Invitrogen) were transferred to sterile 1.5ml tubes and washed three times in 1ml
phosphate buffered saline, pH 7.2 containing 0.1% bovine serum albumen (PBS-
BSA) using the magnetic particle collector. Serum obtained from rabbits inoculated
with cell-surface extracts of non-toxigenic C. botulinum type C (MPRL 2510) was
diluted 1 in 100, 1 in 1000 and 1 in 10000 in PBS-BSA. The beads were re-
suspended in 1ml of the serum dilutions and incubated overnight at 4°C on a rotating
mixer.
Beads were washed four times in PBS and re-suspended in a 1 in 1000 dilution of
anti-rabbit IgG-FITC conjugate in PBS. Fluorescence microscopy was used to
determine which serum dilution gave adequate coating of the beads.
On the basis of this, a 1 in 100 serum dilution was used for all further IMS work.
Sample preparation for IMS
Pre-coated beads stored in PBS-BSA with sodium azide were transferred to an
anaerobic workstation and washed twice in pre-reduced PBS-BSA. All wash steps
were carried out in a volume of 1ml.
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Pure culture of C. botulinum type C
An overnight culture of C. botulinum type C (MPRL 4564) was diluted to give a
concentration of lxl06 cells/ml based on total cell counts using a Thoma cell
counting chamber.
Mixed bacterial culture
Overnight broth cultures of C botulinum type C (MPRL 4564), C. sporogenes
(MPRL 2591) C. sordelli (MPRL 2645) and C. perfringens (MPRL 2661) were each
diluted to a concentration of lxlO6 cells/ml based on total cell counts and equal
volumes combined. Duplicate tubes were also set up with 0.1% Tween-20 added to
the nutrient broth used in the washing stages to reduce non-specific binding of
bacteria to the beads.
Spiked faecal enrichment culture
Approximately lg healthy horse faeces was added to 5ml pre-reduced AIM-CMB
and transferred to an anaerobic workstation. An overnight culture of C. botulinum
type C was diluted to a concentration of lxl06 cells/ml and 0.5ml added to the faecal
enrichment culture. Following 48h incubation, the culture supernate was diluted 1 in
100, 1 in 1000 and 1 in 10000.
Recovery of C. botulinum type C
The beads were initially incubated with 1ml of the bacterial suspension on a rotating
mixer for 15min, 30min, 45min or 60min. On the basis of the initial experiment
using a pure culture of C. botulinum type C, subsequent samples were incubated with
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the beads for 30 min. Following incubation, beads were washed four times in pre-
reduced nutrient broth with the addition of 0.1% Tween-20 and re-suspended in 1ml
nutrient broth from which dilutions of 1 in 10 and 1 in 100 were prepared and 20pl
aliquots used to inoculate FAA plates for viable cell counts following 24h incubation
at 30°C. The starter culture was also plated out at the same dilutions for viable cell
counts in order to determine the percentage recovery.
Recovery of Group III Clostridia from enrichment cultures
Enrichment broth cultures of equine gastrointestinal contents following 48h
incubation were diluted 1 in 100, 1 in 1000 and 1 in 10000 and subjected to the
immunomagnetic separation procedure as previously described. The resulting bead
suspension was diluted to 1 in 100, 1 in 1000 and 1 in 10000 and used to inoculate
EGS plates. Plates were checked after 24h incubation at 30°C and representative
colonies were sub-cultured to obtain pure cultures and stored in cooked meat broths
to be used as stock cultures.
2.1.10. Direct detection of BoNT/C by ELISA
Processing of samples for detection of BoNT/C
For the detection of BoNT/C, isolates obtained from the enrichment cultures of
equine gastrointestinal contents were inoculated into fresh AIM-CMB and incubated
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anaerobically at 30°C for 4 days. The culture supernate was removed and centrifuged
at 1 OOOOg for 10 min and the supernate collected and stored at -20°C.
ELISA to detect BoNT/C
A sandwich ELISA for the detection of BoNT/C had been developed by CAMR,
Porton Down. A polyvalent guinea pig antiserum (supplied by CAMR) raised against
the purified neurotoxin was used as a capture antibody. Nunc Immuno™ Polysorp™
ELISA strips (Fisher Scientific UK, Loughborough, Leicestershire, UK) were coated
(100(jl per well) overnight at 4°C with 5-lOpg/ml of the antiserum diluted in PBS
pH 7.4. Plates were washed four times with PBS containing 0.1% Tween 20 (PBS-
T).
Plates were blocked with PBS containing 3% teleostean gelatine (PBS-TG; Sigma;
200|Jl per well) for 2h at 37°C in a shallow water bath and then washed four times in
PBS-T and stored at -20°C until use.
Culture supernates were assayed in duplicate at two dilutions (undiluted and 1 in 4
for direct detection and undiluted and 1 in 10 for enrichment cultures). Samples were
diluted in PBS-TG and lOOpl added to each well. The plates were incubated at 37°C
for 90min, with shaking, and then washed four times with PBS-T.
To detect the BoNT/C, the anti-BoNT/C guinea pig IgG (supplied by CAMR),
conjugated to horseradish peroxidase (HRP) was used at a dilution of 1 in 300 in
PBS-TG (lOOpl per well). Plates were incubated for 90 min at 37°C and then washed
four times in PBS-T.
The substrate (3, 3\ 5, 5'-tetramethyl-benzidine dihydrochloride tablets, Sigma)
dissolved in phosphate-citrate buffer pH 5.0 with 2pl 30% H2O2 per 100ml, was
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added to the plate (lOOpl per well). The reaction was allowed to develop at room
temperature for 30min or until the background became detectable. The reaction was
stopped by the addition of 2M H2SO4 (50pl per well). The absorbance was measured
at 450nm, reference at 620nm, in an Anthos plate reader.
Controls
Purified BoNT/C was diluted in PBS-TG to 200ng/ml, 50ng/ml, 12.5ng/ml,
3.12ng.ml and 0.8ng/ml and was included as a standard to enable comparison
between plates and quantification of levels of toxin detected.
Columns 1, 6, 7 and 12 were not coated, receiving only PBS-G (lOOpl/well) during
the coating stage. Each sample was therefore added to two coated wells and one
uncoated well. The uncoated well was used as a control for non-specific binding of
the sample to the plate. Two rows of wells received no samples, only PBS-G
(lOOpg/well) as a negative control.
Calculation of ELISA results
The mean OD for the negative control was subtracted from the mean OD for the
sample in the coated wells and from the OD of the sample in the uncoated well. The
OD for the uncoated well (minus the negative control) was then subtracted from the
mean sample OD. This value was used to calculate the amount of BoNT/C present in
the samples, using the standard BoNT/C curve and correcting for dilution factors.
Samples were considered positive if the final OD value was equal to or greater than
that for the 0.8ng/ml BoNT/C standard.
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2.1.11 Detection of the BoNT/C gene in enrichment cultures by PCR
Processing of samples for DNA extraction
Approximately lg of each of the gastrointestinal content and tissue samples was
added to 5ml pre-reduced AIM-CMB (Brown et al, 1996) and transferred to an
anaerobic cabinet. After 24h and 5 days incubation at 30°C, a 1ml aliquot of culture
supernate was removed, centrifuged at lOOOOg for 5 min and the pellet stored at -
20°C.
Extraction of DNA for PCR
The pellet was resuspended in 597pl Tris-EDTA buffer pH8.0 (TE buffer; lOmM
Tris and ImM EDTA) with 3pl Proteinase K (20mg.ml"1) and lysed using a Mini
Bead Beater-8 (BioSpec Products Ltd) for 3 min with 0.1mm silica/zirconium beads
(BioSpec Products Ltd). The supernate was removed to a fresh tube with lOOpl 5M
NaCl and 80pl CTAB solution was added to precipitate humic acids and incubated at
37°C for lOmin. An equal volume of chloroforrmisoamyl alcohol mixture (Sigma)
was added and shaken to form an emulsion before centrifugation at lOOOOg for 5min.
The clear fraction was removed to a fresh tube and an equal volume of
phenol:chloroform:isoamyl alcohol mixture was added (Sigma), shaken to form an
emulsion and centrifuged at lOOOOg for 5 min. The aqueous supernate was removed
and the DNA precipitated by the addition of 0.6 volumes isopropanol. The tube was
gently shaken and centrifuged at lOOOOg for 1 min to pellet the DNA. The
supernatant was removed and the pellet washed with 70% ethanol and centrifuged at
lOOOOg for 5 min. The pellet was dried in a 37°C incubator for 10 min and re-
suspended in lOOpl TE buffer overnight at 4°C.
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Detection of the Group III clostridial genes by PCR
PCR detection of the genes for the BoNT/C, BoNT/D, C2 toxin and C. novyi alpha
toxin was carried out using the primer sets and reaction conditions detailed in Table
2.2, Table 2.3 and Table 2.4.
2.1.12 Sequence analysis of BoNT/C PCR products
Preparation of samples for sequencing.
PCR products generated using the Tox384/1049 primer pair were separated by
agarose gel electrophoresis and the bands excised using sterile disposable scalpels
over an ultraviolet light source. The PCR product was extracted from the gel using
the MinElute Gel Extraction kit (Qiagen) according to the manufacturer's protocol
and used as the DNA template for the PCR reaction using the Tox625/Tox850 primer
pair. PCR products were separated by agarose gel electrophoresis and the PCR
products extracted from the gel using the MinElute Gel Extraction kit (Qiagen). The
absorbance at A280/A260 was measured to quantify the amount ofDNA present and
the PCR products were sent to the Moredun Institute for sequencing (Functional
Genomics Unit, Moredun Research Institute, Edinburgh, UK).
Analysis of sequence data
Sequence data was converted into FASTA format using the Chromas 2 program and
entered into a BLAST search for comparison with published gene sequences. All
sequences that were found to match, or partially match, the BoNT/C sequence were
aligned using Multalin (Corpet, 1988).
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2.1.13 Detection of BoNT/C gene products by Southern blotting
After separation by agarose gel electrophoresis, PCR products were denatured by
incubation in denaturation buffer (1.5M NaCl; 0.5M NaOH) for 30min at room
temperature with gentle shaking followed by incubation in neutralisation buffer (1M
Tris-Cl; 1.5M NaCl, pH 7.4) for 30 min at room temperature with gentle shaking.
PCR products were then transferred to positively charged nylon membrane (0.45pm
pore size) overnight in 10X sodium citrate buffer (SSC; 1.5M NaCl, 0.15M sodium
citrate, pH 7.0). The gel was discarded and the PCR products cross linked to the
nylon membrane by exposure to UV light for 30s. The nylon membrane was then
incubated in Pre-hybridisation buffer containing 5xSSC; 0.1% N-laurolysarcosine
(w/v), 0.02% SDS (w/v) and 1% Blocking solution. DIG labelled probes (MWG
Biotech) were denatured at 95°C for 10 min and diluted 1:10000 in Pre-hybridisation
buffer and incubated with the membrane overnight at 60°C. All of the following
steps were carried out at room temperature with gentle shaking. The nylon membrane
was washed twice in SSC (2x) with 0.1%SDS, then washed twice in 0.5xSSC with
0.1%SDS and blocked for 30min with Blocking solution (Roche). Following
blocking, the nylon membrane was incubated in a 1:5000 dilution of anti-DIG
antibody in blocking solution and washed twice in Washing buffer (Roche). The
nylon membrane was then incubated in Detection buffer for 5min before developing
in freshly prepared substrate solution in the dark. When the required colour intensity
was achieved the reaction was stopped by rinsing in double distilled water.
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Screening of BoNT/C PCR products by slot blotting
Slot blotting of PCR products to detect the BoNT/C gene from enrichment cultures
was carried out using the Bio-Dot Microfiltration apparatus (Bio-Rad). Nylon
membrane (0.45(Jm pore size, Roche) was soaked in SSC for 10 min and the slot
blotting apparatus assembled according to the manufacturer's guidelines. Wells were
rinsed with lOOpl distilled water and 75pl PCR products applied to the membrane
and pulled through using a vacuum pump. The membrane was removed and placed,
face up on a sheet of filter paper soaked in 10%SDS solution for 5 min, then placed
on filter paper soaked in denaturation buffer for 5 min, neutralisation buffer for 5 min
and finally SSC (2x) for 5 min. The membrane was exposed to ultraviolet light for
30s in a transilluminater and then incubated in Pre-hybridisation buffer containing
5xSSC; 0.1% N-laurolysarcosine (w/v). 0.02% SDS (w/v) and 1% Blocking solution
overnight at 60°C. DIG labelled probes (MWG Biotech) were denatured at 95°C for
10 min and diluted 1:10000 in Pre-hybridisation buffer and incubated with the
membrane overnight at 60°C. All of the following steps were carried out at room
temperature with gentle shaking. The nylon membrane was washed twice in SSC
(2x) with 0.1%SDS, washed twice in 0.5xSSC with 0.1%SDS and blocked for 30min
with blocking solution. Following blocking, the nylon membrane was incubated in a
1:5000 dilution of anti-DIG antibody in blocking solution and washed twice in
Washing buffer. The nylon membrane was then incubated in Detection buffer for
5min before developing in freshly prepared substrate solution in the dark. When the
required colour intensity was achieved the reaction was stopped by rinsing in double
distilled water.
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2.2 Detection of Group III toxin genes in C. novyi type A, C. botulinum
type C and C. botulinum type D
2.2.1 Bacterial strains
Bacterial strains of Group III organisms were obtained from the National Culture of
Type Strains (NCTC, Central Public Health Laboratory, London, UK), the Glaxo
collection and the MPRL collection, the Public Health Laboratory Service (PHLS),
the Anaerobe Reference Unit (ARU; Cardiff) (Table 2.5).
2.2.2 Culture of strains for DNA extraction
Bacterial strains from the laboratory freeze-dried culture collection were inoculated
into pre-reduced AIM-CMB and transferred to an anaerobic workstation. Following
overnight incubation at 30°C, strains were plated onto Fastidious Anaerobe Agar
(Lab M, Bury, UK) supplemented with 10% egg yolk emulsion (Oxoid, Basingstoke,
UK). Plates were checked after 24h and 48h incubation at 30°C.
2.2.3 Extraction of DNA for PCR
DNA was extracted from plated colonies using Chelex 100 chelating resin (Bio-Rad,
Richmond, CA) according to the method of de Lamballerie et al (1992).
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Lab No. Organism Source
141 C. novyi type A-like Horse ileum (subacute EGS)
465 C. novyi type A Wound site (common bile duct drain)
2306 C. novyi type A Source not known
2307 C. novyi type A Source not known
2510 C. botulinum type C NCTC 3732
2530 C. novyi type A NCTC 538
2531 C. novyi type A Glaxo collection
2533 C. novyi type A NCTC 6735
2534 C. novyi type A Source not known
2535 C. novyi type A Source not known
2536 C. novyi type A Source not known
3209 C. novyi type A PHLS 2680
3341 C. novyi type A Soil ( St. Kilda)
3923 C. botulinum type D NCTC 8265
4540 C. novyi type A Injection site (Glasgow)
4541 C. novyi type A Injection site (Glasgow)
4545 C. novyi type A Crush injury wound swab
4547 C. novyi type A Injection site (PHLS Cardiff)
4548 C. novyi type A Injection site (PHLS Cardiff)
4549 C. novyi type A Horse ileum (AGS)
4550 C. novyi type A Horse ileum (AGS)
4551 C. novyi type A Horse ileum (AGS)
4552 C. novyi type A Hare with dysautonomia, small intestine
4553 C. novyi type A Hare with dysautonomia, small intestine
4554 C. novyi type A Hare with dysautonomia, small intestine
4556 C. novyi type A Horse faeces, CGS
4557 C. novyi type A Horse faeces, recovered CGS
4558 C. novyi type A Horse faeces, contact EGS
4559 C. novyi type A Horse faeces, contact EGS
4561 C. novyi type A Horse ileum, AGS
4562 C. novyi type A Horse ileum, CGS
4563 C. novyi type A Horse faeces, CGS
4564 C. botulinum type C NCTC 8548
4565 C. botulinum type C NCTC 10914
4566 C. novyi type A Injection site (Glasgow)
4567 C. novyi type A Injection site (Glasgow)
4568 C. novyi type A NCTC 6738
4569 C. novyi type A Injection site (Dublin)
4570 C. novyi type A ARU collection
4571 C. novyi type A NCTC 538
4572 C. novyi type A Injection site (Bournemouth)
4573 C. novyi type A Injection site (Glasgow)
4574 C. novyi type A Injection site (Glasgow)
4575 C. novyi type A Injection site (Stockton)
Table 2.5: Group III reference strains used. All isolates are from human
sources unless otherwise stated.
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2.2.4 PCR detection of Group III clostridial toxin genes
PCR for the detection of the BoNT/C, BoNT/D, C2CI, C2CII and novyi alpha toxin
genes was carried out using the primers detailed in Table 2.2. PCR reaction and
cycling conditions are given in Table 2.3 and Table 2.4.
2.2.5 Sequence analysis of the C2CI and 16s rRNA PCR products
Extraction and sequencing of the C2CI and 16s rRNA PCR products was performed
as described for the sequencing of the BoNT/C gene PCR products (Chapter 2.1.12)
2.2.6 Heteroduplex mobility assay
PCR using the 16SF/16SR primer pair was performed as previously described and
5pl PCR product from each of the clostridial strains (Table 2.1) or the Group Ill-type
organisms (Table 2.5) were combined with 5pl PCR product from C. botulinum type
C (MPRL 4564) in denaturing buffer (1M NaCl, lOOmM Tris-HCl, 20mM disodium
EDTA, pH 8.0) and incubated at 95°C for 10 min. Products were separated on a slab
gel (12.5% acrylamide in 5X TBE). Gels were stained with lmg/ml ethidium
bromide in 0.6X TBE and visualised using ultraviolet light.
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2.3 Detection of botulinum neurotoxins and Group III clostridial toxins
in seabirds
2.3.1 Direct detection of BoNT/C by ELISA
Approximately lg/lml of each sample of the gastrointestinal contents of seabirds
was added to 5ml pre-reduced AIM-CMB and transferred to an anaerobic
workstation. Following incubation at 30°C for 24h and 4 days, a 1ml aliquot of
culture supernate was removed and centrifuged at lOOOOg for 10 min and the
supemate stored at -20°C for toxin detection. The pellet was also stored at -20 °C
for DNA extraction.
Serum samples were centrifuged at 13000rpm for 10 min and the supernatant used
directly for the detection of BoNT/C by ELISA (Chapter 2.1.10).
2.3.2 Detection of toxin genes by PCR
Extraction of DNA for PCR
DNA was extracted from the pellets of enrichment cultures of the gastrointestinal
contents of seabirds (Table 2.7) using the QIAamp DNA Stool Mini Kit (Qiagen)
according to the manufacturer's protocol. PCR primer details and reaction conditions
for the detection of the BoNT/A, BoNT/B, BoNT/C, BoNT/D and BoNT/E genes
and the novyi alpha toxin gene and C2CI and C2CII genes are given in Table 2.2,
Table 2.3 and Table 2.4.
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Sample Source
B303427/1 GI contents (herring gull)
B303427/2 GI contents (herring gull)
B303467 GI contents (gannet)
B303515/1 GI contents (herring gull)
B303515/2 GI contents (herring gull)
B303534/2 GI contents (herring gull)
B303853/1 Liver and Intestine (herring gull)
B303853/2 Liver and Intestine (herring gull)
B303853/3 Liver and Intestine (herring gull)
B303853/4 Liver and Intestine (herring gull)
B303855/1 GI contents (herring gull)
B303855/2 GI contents (herring gull)
B303855/3 GI contents (herring gull)
B303855/4 GI contents (herring gull)
B303855/5 GI contents (herring gull)
B303855/6 GI contents (cormorant)
B304150 Intestine from 5 herring gulls (mixed sample)
B301155a Leeches recovered from herring gulls
B301155b Leeches recovered from herring gulls
B301155c Leeches recovered from herring gulls
Table 2.7: Seabird samples used. All samples provided by the Scottish
Agricultural College (Ayr, Scotland)
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2.4 Detection of C. tetani
2.4.1 isolation of C. tetani
Four samples of soil and environmental material were collected from St. Kilda.
Approximately lg of each sample was added to 5ml pre-reduced AIM-CMB and
transferred to an anaerobic workstation. The resulting broth cultures were used to
inoculate Colombia Blood Agar plates containing Colombia agar base (Oxoid,
Basingstoke, UK) supplemented with 5% horse blood (Oxoid, Basingstoke, UK)
after Oh, 24h and 48h incubation at 37°C. Plates were incubated at 37 °C and were
checked at 24h intervals for the presence of fine swarming growth. Any finely
swarming colonies were subcultured onto CBA containing 4% agar and incubated at
37 °C. Plates were checked for the presence of faintly haemolytic colonies. After 24h
and 4 day incubation 1ml culture supernate was removed, centrifuged at lOOOOg for
10 minutes and the pellet stored at -20 °C for DNA extraction.
C. tetani was presumptively identified by morphology when examined by phase
contrast microscopy and Gram stain by light microscopy (Gram positive rods with
circular terminal or sub-terminal spores).
Forty samples of "Fulmar oil" (stomach contents of nestlings spat out as a form of
defence) were collected from nesting birds in the Firth of Forth and stored at -20 °C.
Approximately 1ml of each sample was added to pre-reduced AIM-CMB for the
isolation of C. tetani as above. Oil samples were also plated directly onto CBA plates
and incubated at 37 °C in an anaerobic workstation.
76
2.4.2 Detection of the Tetanus neurotoxin by PCR
DNA was extracted from the pellets of enrichment cultures of soil and Fulmar oil
samples using the QIAamp DNA Stool Mini Kit (Qiagen) according to the
manufacturer's protocol.
All PCR reaction were carried out in lOOpl reaction buffer (Sigma) containing
3.75mM MgCh, 50nM of each primer, 200pM dNTP, 5pl DNA template and 1.25U
RedTaq (Sigma). The primers were taken from a published sequence (Flalpem et al,
1990). PCR cycling conditions are given in Table 2.8.
PCR products were separated on a 1.5% agarose gel in TAE buffer (40mM Tris and
2mM disodium EDTA, pH8.0) containing ethidium bromide (O.lmg/ml). Products
were visualised under ultraviolet light. The readyload lOObp DNA ladder




Gene Initial Cycles Cycling Final
denaturation conditions extension
TetC 5 min at 94°C 25 2 min at 94°C 5 min at 67°C
3min at 30°C
lOmin at 67°C
Table2.8: PCR cycling conditions for the detection of the gene for Fragment
C of the Tetanus neurotoxin.
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Chapter Three
Isolation and Characterisation of Group III organisms from equine
gastrointestinal contents
The aetiology of grass sickness remains unknown though serological data supports
the current hypothesis that grass sickness is caused by an intoxification with C.
botulinum type C (Hunter and Poxton 2001; MacCarthy et al. 2004).
In order to further investigate the possible relationship between Equine Grass
sickness and C. botulinum type C the following work was carried out.
3.1 Results
3.1.1 Isolation of Group III organisms
All culture work was carried out in conjunction with Bob Brown and Fraser Pike
(MPRL). A total of 464 isolates were collected from the enrichment culture of tissue
and gastrointestinal contents of horses with histopathologically confirmed cases of
grass sickness, and from faecal samples taken from co-grazers (Figure 3.1). From the
control horses used in the study 128 isolates were obtained. All isolates were Gram
positive rods as seen under a light microscope and produced lecithinase, lipase or
both on EYA. The organisms were sub-cultured on EYA plates until pure cultures
were obtained. Seven of the isolates obtained from horses with EGS produced
proprionic and butyric volatile fatty acids (VFA) along with varying amounts of










Pharynx Stomach Liver Spleen Ileum Jejunum Duodenun Caecum Colon Rectum Faeces


















Pharynx Stomach Liver Spleen Ileum Jejunum Duodenui Caecum
Anatomical Site
Colon Rectum Faeces
Figure 3.2: Source of isolates obtained from control horses
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Isolate Source of isolate Sample type Volatile fatty acids
RBGS 553 Horse 02/351 Liver APb
RBGS116 Horse 02/352 Faeces apB(iv)
RBGS 559 Horse 02/352 Faeces (co-grazer) APB
RBGS 486 Horse 02/376 Pharynx aPB(v)
RBGS 488 Horse 02/376 Pharynx PBv(a)
RBGS 637 Horse 03/342 Rectal contents PBv(a)
RBGS 887 Horse 02/392 Faeces (co-grazer) Apb
Table 3.1: GLC profiles of isolates identified as Group III Clostridia and
description of the animal and sample from which they were obtained. P =
proprionic acid, B = butyric acid, A = acetic acid, V = valeric acid. Letters in
upper case represent levels of fatty acids above 10pmoles/ml, letters in lower
case represent levels of fatty acids between 1-10 pmoles/ml, and letters in
brackets represent levels of fatty acids between 0.2 - 1 pmoles/ml.
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3.1.2 Characterisation of isolates
A random sample of 64 isolates were investigated for the presence of clostridial toxin
genes by PCR in conjunction with Allison Wroe (MPRL), 29 had been isolated from
horses with confirmed grass sickness, 10 from faeces of co-grazers of cases with
grass sickness and 25 from the control animals.
Grass Sickness isolates
Of the isolates obtained from grass sickness samples, 16 were found to contain no
toxin genes by PCR. Phenotypic characterisation of these isolates shows that 9 of the
isolates resemble C. sporogenes and were found throughout the GI tract, 5 of the
isolates were novyi-like and these were found only in the large intestine. In addition
one isolate was found to resemble C. sordelli and one C. septicum.
None of the isolates tested were found to contain the A, B, C or D botulinum
neurotoxins or the C. novyi a toxin genes by PCR. Toxigenic isolates were found in
a variety of samples types (Table 3.2). Six of the isolates appeared to have atypical
toxin profiles for the phenotype and one isolate (544) appeared to have an unusual




Isolate # Source Phenotype C2CI C2CII BoNT/E C. perfringens a
toxin
115 Faeces (CGS) sporogenes-like + - NCR NCR
266 Ileum perfringens-like - - NCR +
340 Spleen perfringens-like + - NCR NCR
423 Colon perfringens-like - + NCR NCR
459 Pharynx perfringens-like - - NCR +
498 Colon perfringens-like - - NCR +
528 Caecum novyi-like - - - +
544 Colon novyi-like - + + -
548 Caecum perfringens-like - - - +
624 Duodenum perfringens-like - - - +
633 Duodenum sporogenes-like - - - +
659 Stomach novyi-like - - - +
722 Rectum novyi-like + - NCR NCR
Table 3.2 Phenotype and toxin gene profile of toxigenic isolates (n=13) from
grass sickness cases.
NCR - no consistent result obtained for this isolate.
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Co-grazer isolates (faecal isolates only)
No isolates were found to contain the genes for the A, B, C, D or E botulinum
neurotoxins or the C. novyi a toxin. The majority of the isolates examined resemble
C. novyi. One isolate resembled a Group I botulinum-like organism, one C. sordelli
and one C. sporogenes. Two isolates were found to carry genes for one or more
component of the C2 toxin. Isolate 147 contains only the CI component and isolate
895 contains both components of the C2 toxin gene.
Control animal isolates
Twenty-five of the isolates studied were from control animals. Of these 17 were
found to contain no toxin genes by PCR. The majority of the isolates (12) were found
to be novyi-like by phenotypic characterisation with 8 resembling C. sporogenes, 3
resembling C. perfringens and 1 resembling C. sordelli. No isolates were found to
contain the A, B, C, D or E botulinum neurotoxins or the C. novyi a toxin genes.
Toxigenic isolates were found throughout the GI tract (Table 3.3). Again atypical
isolates were found; isolate 411 contains genes characteristic of the Group III
Clostridia but phenotypically resembles C. sporogenes and isolate 725 contains genes
typical of both C. perfringens and the Group III Clostridia.
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C. perfringens a toxin
411 Jejunum sporogenes-like + - NCR
464 Pharynx UD - + NCR
468 Pharynx perfringens-like - - +
607 Spleen perfringens-like + - NCR
675 Caecum perfringens-like - - +
725 Rectum sporogenes-like - + +
748 Caecum novyi-like + - NCR
786 Colon novyi-like + - NCR
Table 3.3 Phenotype and toxin gene profile of toxigenic isolates from control
animals.
NCR - no consistent result obtained for this isolate
UD - phenotype could not be determined on the basis of biochemical properties or GLC
profile.
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3.1.3. Immunomagnetic separation of Group III Clostridia
An immunomagnetic separation technique for the isolation of Group III Clostridia
was developed. Magnetic beads coated in anti-rabbit antibodies (Dynatech) were
coated overnight in the pooled serum from rabbits inoculated with whole killed cells
of a non-toxin producing strain of C. botulinum (MPRL 4565) on a rotating mixer at
4°C. Coating was verified using fluorescence microscopy with FITC labelled anti
rabbit immunoglobulin.
Coated beads were incubated anaerobically with a pure culture of C. botnlinum in
pre-reduced AIM/CMB for 15, 30, 45 and 60 mins to determine the optimum time
for binding of bacterial cells to the coated beads. The resulting suspension was used
to inoculate both AIM/CMB to check for toxin production and FAA plates to
determine the percentage recovery.
The optimum recovery of cells was 33.5% after 30 mins incubation with the
magnetic beads. An incubation time of 10 mins gave 23% recovery; 45 mins
incubation gave a recovery of 13.5% and 60 mins incubation gave a recovery of only
8.6%.
In mixed clostridial cultures (C. botulinum type C, C. sporogenes, C. sordelli and C.
perfringens) recovery of C. botulinum was poor (16.5%) and hard to distinguish from
remaining C. sporogenes. The addition of TWEEN-20 gave a 45% recovery of C.
botulinum though large numbers of C. perfringens remained.
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As this technique gave a 57.5% recovery of C. Botulinum type C from spiked healthy
horse faeces it was applied to two samples from the Dubai study; the ileal contents
from horse 03/342 and from the large colon contents of 'Horse G'. A representative
sample of the colony types produced were further purified and characterised by
phenotypic methods and direct detection of the BoNT/C as well as PCR detection of
toxin genes (Table 3.4). All of the isolates characterised phenotypically appear to
have atypical toxin profiles for their phenotype with none resembling Group III
Clostridia. Two of the isolates that tested positive for the BoNT/C gene by PCR gave
bands of an atypical size of approximately 600bp rather than the expected 460bp
based upon the published sequence, but were found to produce detectable levels of
the BoNT/C by ELISA-based toxin assay.
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1 Ileum C. bifermentans - like 14.4 +* - -
2 Ileum C. sordelli - like 8.4 +* + +*
3 Ileum C. perfringens - like 15 + + -
4 Ileum UD 8 - + +
5 Ileum UD <0.8 - - +
6 Colon C. perfringens - like 14.8 + +* +
7 Colon UD <0.8 - - -
8 Colon C. sordelli - like <0.8 +* - +*
Table 3.4. Phenotype, toxin gene profile and toxin production of isolates
obtained by immunomagnetic separation
*
- PCR product not expected size
UD - phenotype could not be determined on the basis of biochemical properties or GLC
profile.
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3.1.4. Investigation of Group III clostridial genes in enrichment
cultures from horses with Grass Sickness by PCR
PCR detection of the BoNT/D gene
PCR with the BoNT/D primers produced a 497bp product from DNA of C.
botulinum type D demonstrating the presence of the BoNT/D gene. None of the
DNA extracts from enrichment cultures were found to contain the gene.
PCR detection of the C2 toxin gene
PCR with the C2CI primers amplified a 310bp product in the C. botulinum type C
strain (MPRL 1464) demonstrating the presence of the component I gene of the C2
toxin. Additional bands of varying sizes between 500 and 900 bp were amplified
from all of the samples with many also producing a 310bp product (Fig3.3).
PCR with the C2C11 primers amplified a 1093bp product with DNA from the
C. botulinum type C strain (MPRL 4564) demonstrating the presence of the
component II gene of the C2 toxin. None of the gut enrichment cultures





Figure 3.3. Detection of the C2CI gene by PCR in DNA from enrichment
cultures from horse EBV 03/409/ Lanes 1, 12, 13 and 24, 100bp DNA ladder;
lane 2, ileum day 1 enrichment; lane 3, ileum day 5 enrichment; lane 4,
jejunum day 1 enrichment; lane 5, jejunum day 5 enrichment; lane 6,
duodenum day 1 enrichment; lane 7, duodenum day 5 enrichment; lane 8,
pharynx day 1 enrichment; lane 9, pharynx day 5 enrichment; lane 10, liver
day 1 enrichment; lane 11, liver day 5 enrichment; lane 14, stomach day 1
enrichment; lane 15, stomach day 5 enrichment; lane 16, colon day 1
enrichment; lane 17, colon day 5 enrichment; lane 18, caecum day 1
enrichment; lane 19, caecum day 5 enrichment; lane 20, rectum day 1
enrichment; lane 21, rectum day 5 enrichment; lane 22 MPRL 4564 (positive
standard); lanes 23 Negative control.
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PCR detection of the BoNT/C gene in GS horses
PCR with the Tox384 and Tox850 primers produced unusual products of varying
sizes with the DNA extracted from the enrichment cultures ofwhole gut samples.
A product of approximately 466bp was produced from the DNA of C. botulinum
type C (MPRL 4564) demonstrating the presence of the BoNT/C gene and the
correct working of the primers. The same result was seen when the PCR was
repeated with the Toxl049 and Tox625 primers with a product of approximately
424bp produced from the DNA of C. botulinum type C (MPRL 4564) and multiple
products of varying sizes produced from DNA extracted from whole gut enrichment
cultures.
PCR using the Toxl049 and Tox384 primers was carried out on the following
samples; duodenum (day 5) and spleen (day 1 and day 5) from EBV 02/352,
duodenum (day 1 and day 5), colon (day 1 and day 5) and pharynx (day 5) from EBV
03/409 and duodenum (day 1 and day 5), liver (day 5) and rectum (day 1) from EBV
03/425. A total of 20 bands of varying sizes were extracted from agarose gel and re-
amplified using a nested PCR reaction with primers Tox625 and Tox850 to check for
single products. Sequence analysis of the 14 PCR products giving single bands gave
4 sequences that matched the gene sequence of BoNT/C when entered into a BLAST
search. These sequences were obtained from the following samples; duodenum and
rectum from EBV 03/425 and duodenum and pharynx from EBV 03/409. Sequence
alignment using the multalin program gave 2 consensus sequences that were used to
create DNA probes (Fig 3.4).
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Figure 3.4. Sequence alignment of data obtained from enrichment cultures
of horses with grass sickness amplified using the Tox625 primers. Sequence
16, duodenum day 1 enrichment from EBV 03/425; sequence 10, rectum day
1 enrichment from EBV 03/425; sequence 5, duodenum day 1 enrichment
from EBV 03/409; sequence 7, pharynx day 5 enrichment from EBV 03/409.
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PCR and Southern blot analysis of BoNT/C gene
Primary and nested PCR reactions using the Toxl049/Tox384 and Tox850/Tox625
primers respectively were run on all DNA extracted from gut enrichment cultures
and the products visualised on agarose gel electrophoresis (Fig. 3.5). Of the 456 PCR
products screened by Southern blotting, 13 tested positive for the presence of the
BoNT/C gene (Table 3.5). This was repeated and Southern blot analysis of products
separated on agarose gels was performed to confirm the positive result and to check
the sizes of the products produced. Of these, 8 of the samples gave bands of
approximately 450bp and 200bp as seen with the positive control and 2 produced
bands of approximately 900bp.
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Figure 3.5a: Detection of the BoNT/C toxin gene by PCR in DNA from
enrichment cultures from horse EBV 02/352. Lanes 1 and 26, 100bp DNA
ladder; lane 2, ileum day 1 enrichment; lane 3, ileum day 1 enrichment
nested PCR; lane 4, ileum day 5 enrichment; lane 5, ileum day 5 enrichment
nested PCR; lane 6, duodenum day 1 enrichment; lane 7, duodenum day 1
enrichment nested PCR; lane 8, duodenum day 5 enrichment; lane 9,
duodenum day 5 enrichment nested PCR; lane 10, spleen day 1 enrichment;
lane 11, spleen day 1 enrichment nested PCR; lane 12, spleen day 5
enrichment; lane 13, spleen day 5 enrichment nested PCR; lane 14, liver day
1 enrichment; lane 15, liver day 1 enrichment nested PCR; lane 16, liver day
1 enrichment; lane 17, liver day 5 enrichment nested PCR; lane 18, pharynx
day 1 enrichment; lane 19, pharynx day enrichment nested PCR; lane 20,
pharynx day 5 enrichment; lane 21, pharynx day 5 enrichment nested PCR;
lane 22, jejunum day 1 enrichment; lane 23, jejunum day 1 enrichment
nested PCR; lane 24, jejunum day 5 enrichment; lane 25, jejunum day 5
enrichment nested PCR; lane 27, colon day 1 enrichment; lane 28, colon day
1 enrichment nested PCR; lane 29, colon day 5 enrichment; lane 30, colon
day 5 enrichment nested PCR; lane 31, stomach day 1 enrichment; lane 32,
stomach day 1 enrichment nested PCR; lane 33, stomach day 5 enrichment;
lane 34, stomach day 5 enrichment nested PCR; lane 35, rectum day 1
enrichment; lane 36, rectum day 1 enrichment nested PCR; lane 37, rectum
day 5 enrichment; lane 38, rectum day 5 enrichment nested PCR; lane 39,
caecum day 1 enrichment; lane 40, caecum day 1 enrichment nested PCR;
lane 41, caecum day 5 enrichment; lane 42, caecum day 5 enrichment
nested PCR; lane 43, faeces day 1 enrichment; lane 44, faeces day 1
enrichment nested PCR; lane 45, faeces day 5 enrichment; lane 46, faeces
day 5 enrichment nested PCR.
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Figure 3.5b Detection of the BoNT/C toxin gene by PCR in DNA from
enrichment cultures from horse EBV 03/342. Lanes 1, 26 and 43, 100bp
DNA ladder; lane 2, MPRL 4564 (positive standard); lane 3, MPRL 4564
nested PCR, lanes 4-5 negative controls; lane 6, pharynx day 1 enrichment;
lane 7, pharynx day 1 enrichment nested PCR; lane 8, pharynx day 5
enrichment; lane 9, pharynx day 5 enrichment nested PCR; lane 10, liver day
1 enrichment; lane 11, liver day 1 enrichment nested PCR; lane 12, liver day
5 enrichment; lane 13, liver day 5 enrichment nested PCR; lane 14,
duodenum day 1 enrichment; lane 15, duodenum day 1 enrichment nested
PCR; lane 16, duodenum day 5 enrichment; lane 17, duodenum day 5
enrichment nested PCR; lane 18, ileum day 1 enrichment; lane 19, ileum day
1 enrichment nested PCR; lane 20, ileum day 5 enrichment; lane 21, ileum
day 5 enrichment nested PCR; lane 22, jejunum day 1 enrichment; lane 23,
jejunum day 1 enrichment nested PCR; lane 24, jejunum day 5 enrichment;
lane 25, jejunum day 5 enrichment nested PCR; lane 27, spleen day 1
enrichment; lane 28, spleen day 1 enrichment nested PCR; lane 29, spleen
day 5 enrichment; lane 30, spleen day 5 enrichment nested PCR; lane 31,
rectum day 1 enrichment; lane 32, rectum day 1 enrichment nested PCR;
lane 33, rectum day 5 enrichment; lane 34, rectum day 5 enrichment nested
PCR; lane 35, caecum day 1 enrichment; lane 36, caecum day 1 enrichment
nested PCR; lane 37, caecum day 5 enrichment; lane 38, caecum day 5
enrichment nested PCR; lane 39, stomach day 1 enrichment; lane 40,
stomach day 1 enrichment nested PCR; lane 41, stomach day 5 enrichment;
lane 42, stomach day 5 enrichment nested PCR.
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Figure 3.5c. Detection of the BoNT/C toxin gene by PCR in DNA from
enrichment cultures from horse EBV 03/409. Lanes 1, 20, 21 and 40, 100bp
DNA ladder; lane 2, ileum day 1 enrichment; lane 3, ileum day 1 enrichment
nested PCR; lane 4, ileum day 5 enrichment; lane 5, ileum day 5 enrichment
nested PCR; lane 6, jejunum day 1 enrichment; lane 7, jejunum day 1
enrichment nested PCR; lane 8, jejunum day 5 enrichment; lane 9, jejunum
day 5 enrichment nested PCR; lane 10, duodenum day 1 enrichment; lane
11, duodenum day 1 enrichment nested PCR; lane 12, duodenum day 5
enrichment; lane 13, duodenum day 5 enrichment nested PCR; lane 14,
pharynx day 1 enrichment; lane 15, pharynx day 1 enrichment nested PCR;
lane 16, pharynx day 5 enrichment; lane 17, pharynx day 5 enrichment
nested PCR; lane 18, liver day 1 enrichment; lane 19, liver day 1 enrichment
nested PCR; Iane22, liver day 5 enrichment; lane 23, liver day 5 enrichment
nested PCR; lane 24, stomach day 1 enrichment; lane 25, stomach day 1
enrichment nested PCR; lane 26, stomach day 5 enrichment; lane 27,
stomach day 5 enrichment nested PCR; lane 28, colon day 1 enrichment;
lane 29, colon day 1 enrichment nested PCR; lane 30, colon day 5
enrichment; lane 31, colon day 5 enrichment nested PCR; lane 32, caecum
day 1 enrichment; lane 33, caecum day 1 enrichment nested PCR; lane 34,
caecum day 5 enrichment; lane 35, caecum day 5 enrichment nested PCR;
lane 36, rectum day 1 enrichment; lane 37, rectum day 1 enrichment nested
PCR; lane 38, rectum day 5 enrichment; lane 39, rectum day 5 enrichment
nested PCR.
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Figure 3.5d. Detection of the BoNT/C toxin gene by PCR in DNA from
enrichment cultures from horse EBV 03/425. Lanes 1, 22 and 23, 100bpDNA
ladder; lane 2, colon day 1 enrichment; lane 3, colon day 1 enrichment
nested PCR; lane 4, colon day 5 enrichment; lane 5, colon day 5 enrichment
nested PCR; lane 6, stomach day 1 enrichment; lane 7, stomach day 1
enrichment nested PCR; lane 8, stomach day 5 enrichment; lane 9, stomach
day 5 enrichment nested PCR; lane 10, caecum day 1 enrichment; lane 11,
caecum day 1 enrichment nested PCR; lane 12, caecum day 5 enrichment;
lane 13, caecum day 5 enrichment nested PCR; lane 14, rectum day 1
enrichment; lane 15, rectum day 1 enrichment nested PCR; lane 16, rectum
day 5 enrichment; lane 17, rectum day 5 enrichment nested PCR; lane 18,
pharynx day 1 enrichment; lane 19, pharynx day 1 enrichment nested PCR;
lane 20, pharynx day 5 enrichment; lane 21, pharynx day 5 enrichment
nested PCR; lane 24, spleen day 1 enrichment; lane 25, spleen day 1
enrichment nested PCR; lane 26, spleen day 5 enrichment; lane 27, spleen
day 5 enrichment nested PCR; lane 28, liver day 1 enrichment; lane 29, liver
day 1 enrichment nested PCR; lane 30, liver day 5 enrichment; lane 31, liver
day 5 enrichment nested PCR; lane 32, jejunum day 1 enrichment; lane 33,
jejunum day 1 enrichment nested PCR; lane 34, jejunum day 5 enrichment;
lane 35, jejunum day 5 enrichment nested PCR; lane 36, duodenum day 1
enrichment; lane 37, duodenum day 1 enrichment nested PCR; lane 38,








Figure 3.5e. Detection of the BoNT/C toxin gene by PCR in DNA from
enrichment cultures from horse EBV 02/351. Lanes 1 and 26, 100bp DNA
ladder; lane 2, ileum day 1 enrichment; lane 3, ileum day 1 enrichment
nested PCR; lane 4, ileum day 5 enrichment; lane 5, ileum day 5 enrichment
nested PCR; lane 6, duodenum day 1 enrichment; lane 7, duodenum day 1
enrichment nested PCR; lane 8, duodenum day 5 enrichment; lane 9,
duodenum day 5 enrichment nested PCR; lane 10, liver day 1 enrichment;
lane 11, liver day 1 enrichment nested PCR; lane 12, liver day 5 enrichment;
lane 13, liver day 5 enrichment nested PCR; lane 14, spleen day 1
enrichment; lane 15, spleen day 1 enrichment nested PCR; lane 16, spleen
day 5 enrichment; lane 17, spleen day 5 enrichment nested PCR; lane 18.
pharynx day 1 enrichment; lane 19, pharynx day 1 enrichment nested PCR;
lane 20, pharynx day 5 enrichment; lane 21, pharynx day 5 enrichment
nested PCR; lane 22, stomach day 1 enrichment; lane 23, stomach day 1
enrichment nested PCR; lane 24, stomach day 5 enrichment; lane 25,
stomach day 5 enrichment nested PCR; lane 27, colon day 1 enrichment;
lane 28, colon day 1 enrichment nested PCR; lane 29, colon day 5
enrichment; lane 30, colon day 5 enrichment nested PCR; lane 31, caecum
day 1 enrichment; lane 32, caecum day 1 enrichment nested PCR; lane 33,
caecum day 5 enrichment; lane 34,caecum day 5 enrichment nested PCR;
lane 35, faeces day 1 enrichment; lane 36, faeces day 1 enrichment nested
PCR; lane 37, faeces day 5 enrichment; lane 38, faeces day 5 enrichment
nested PCR; lane 39, faeces day 1 enrichment; lane 40, faeces day 1
enrichment nested PCR; lane 41, faeces day 5 enrichment; lane 42, faeces
day 5 enrichment nested PCR; lane 43, jejunum day 1 enrichment; lane 44,
jejunum day 1 enrichment nested PCR; lane 45, jejunum day 5 enrichment;
lane 46, jejunum day 5 enrichment nested PCR; lane 47, MPRL 4564; lane
48, MPRL 4564 nested PCR.
97
PCR Southern Blot
EBV # MPRL# Source BoNT/C BoNT/C
03/352 3 Duodenum (day 1) + +
Duodenum (day 5) + -
4 Spleen (day 1) + +
Spleen (day 5) + -
10 Rectum (day 1) + +
Rectum (day 5) + -
02/351 25 Ileum (day 1) + +
Ileum (day 5) + -
26 Duodenum (day 1) + +
Duodenum (day 5) + +
03/409 205 Duodenum (day 1) + +
Duodenum (day 5) + -
206 Pharynx (day 1) + -
Pharynx (day 5) + +
209 Colon (day 1) + +
Colon (day 5) + +
03/425 215 Rectum (day 1) + +
Rectum (day 5) + -
221 Duodenum (day 1) + +
Duodenum (day 5) + +
Table 3.5. Detection of BoNT/C by PCR and Southern blotting in enrichment
cultures. A positive PCR result denotes bands of any size detected by
agarose gel electrophoresis. A positive Southern blot result denotes any
sample giving a positive result for BoNT/C by dot blotting. All positive results
were confirmed by repeat PCR and Southern blotting of PCR products
separated by agarose gel electrophoresis.
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3.1.4. Investigation of Group III clostridial genes in enrichment
cultures from control horses by PCR
PCR detection of the BoNT/C gene
Primary and nested PCR reactions using the Toxl049/Tox384 and Tox850/Tox625
primers respectively gave similar banding patterns when separated by agarose gel
electrophoresis as seen with the Grass Sickness horses (Fig 3.6). Southern blot
analysis of the PCR products did not give any positive results indicating that the




Figure 3.6a. Detection of the BoNT/C toxin gene by PCR in DNA from
enrichment cultures from horse EBV 02/182. Lanesl, 18, 19 and 36, 100bp
DNA ladder; lane 2, jejunum day 1 enrichment; lane 3, jejunum day 1
enrichment nested PCR; lane 4, jejunum day 5 enrichment; lane 5, jejunum
day 5 enrichment nested PCR; lane 6, spleen day 1 enrichment; lane 7,
spleen day 1 enrichment nested PCR; lane 8, spleen day 5 enrichment; lane
9, spleen day 5 enrichment nested PCR; lane 10, liver day 1 enrichment;
lane 11, liver day 1 enrichment nested PCR; lane 12, liver day 5 enrichment;
lane 13, liver day 5 enrichment nested PCR; lane 14, ileum day 1
enrichment; lane 15, ileum day 1 enrichment nested PCR; lane 16, ileum day
5 enrichment; lane 17, ileum day 5 enrichment nested PCR; lane 20, rectum
day 1 enrichment; lane 21, rectum day 1 enrichment nested PCR; lane 22,
rectum day 5 enrichment; lane 23, rectum day 5 enrichment nested PCR;
lane 24, caecum day 1 enrichment; lane 25, caecum day 1 enrichment
nested PCR; lane 26, caecum day 5 enrichment; lane 27, caecum day 5
enrichment nested PCR; lane 28, stomach day 1 enrichment; lane 29,
stomach day 1 enrichment nested PCR; lane 30, stomach day 5 enrichment;
lane 31, stomach day 5 enrichment nested PCR; lane 32, colon day 1
enrichment; lane 33, colon day 1 enrichment nested PCR; lane 34, colon day
5 enrichment; lane 35, colon day 5 enrichment nested PCR.
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Figure 3.6b. Detection of the BoNT/C toxin gene by PCR in DNA from enrichment
cultures from horse EBV 02/431. Lanes 1, 24, 25 and 48, 100bp DNA ladder; lane 2,
pharynx day 1 enrichment; lane 3, pharynx day 1 enrichment nested PCR; lane 4,
pharynx day 5 enrichment; lane 5, pharynx day 5 enrichment nested PCR; lane 6,
ileum day 1 enrichment; lane 7, ileum day 1 enrichment nested PCR; lane 8, ileum
day 5 enrichment; lane 9, ileum day 5 enrichment nested PCR; lane 10, duodenum
day 1 enrichment; lane 11, duodenum day 1 enrichment nested PCR; lane 12,
duodenum day 5 enrichment; lane 13, duodenum day 5 enrichment nested PCR;
lane 14, liver day 1 enrichment; lane 15, liver day 1 enrichment nested PCR; lane
16, liver day 5 enrichment; lane 17, liver day 5 enrichment nested PCR; lane 18,
jejunum day 1 enrichment; lane 19, jejunum day 1 enrichment nested PCR; lane 20,
jejunum day 5 enrichment; lane 21, jejunum day 5 enrichment nested PCR; lane 22,
spleen day 1 enrichment; lane 23, spleen day 1 enrichment nested PCR; lane 26,
spleen day 5 enrichment; lane 27, spleen day 5 enrichment nested PCR; lane 28,
ileum day 1 enrichment; lane 29, ileum day 1 enrichment nested PCR; lane 30,
ileum day 5 enrichment; lane 31, ileum day 5 enrichment nested PCR; lane 32,
stomach day 1 enrichment; lane 33, stomach day 1 enrichment nested PCR; lane
34, stomach day 5 enrichment; lane 35, stomach day 5 enrichment nested PCR;
lane 36, caecum day 1 enrichment; lane 37, caecum day 1 enrichment nested PCR;
lane 38, caecum day 5 enrichment; lane 39, caecum day 5 enrichment nested PCR;
lane 40, colon day 1 enrichment; lane 41, colon day 1 enrichment nested PCR; lane
42, colon day 5 enrichment; lane 43, colon day 5 enrichment nested PCR; lane 44,
faeces day 1 enrichment; lane 45, faeces day 1 enrichment nested PCR; lane 46,
faeces day 5 enrichment; lane 47, faeces day 5 enrichment nested PCR.
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PCR detection of BoNT/A, BoNT/B and BoNT/E genes
Multiplex PCR produced a 782bp product from DNA of C. botulinum type A strain
(MPRL 2509); a 205bp product from DNA of C. botulinum type B strain (MPRL
2511) and a 389bp product from DNA of C. botulinum type E strain (MPRL 2512).
PCR with the A/B/E primers did not produce a product with any of the DNA extracts
from enrichment cultures indicating that none of the samples contained the BoNT/A,
BoNT/B or BoNT/E genes.
3.2 Discussion
A large number of isolates were obtained from the anaerobic culture of tissue and
gastrointestinal contents of horses with grass sickness and horse euthanased for non-
GI related causes used as control animals. The isolates picked for purification and
further study were those that resembled Clostridia by colony morphology and do not
represent the total microbiota of the equine gastrointestinal tract. The higher
proportion of isolates obtained from horses with grass sickness has been observed
previously in the faeces of horses with grass sickness (Garrett et al. 2002) though it is
thought that this may reflect the intestinal stasis seen in the disease.
Seven isolates obtained from equine gastrointestinal samples of horses with grass
sickness after enrichment had volatile fatty acid profiles characteristic of the Group
III Clostridia. A further 4 isolates resemble C. novyi on the basis of phenotypic
characteristics. Identification of the Group III Clostridia to species level requires the
detection of the type-specific toxin: BoNT/C for C. botulinum type C, BoNT/D for
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C. botu/inum type D and the C. novyi alpha toxin for C. novyi type A. Each toxin is
encoded by a separate bacteriophage. None of the isolates were found to contain the
genes for any of the major toxins. Four isolates were found to contain the gene for
one or more component of the C2 gene thought these did not resemble typical Group
III organisms by phenotypic characteristics. Seven of the isolates obtained from
enrichment culture of faeces from co-grazers resembled C. novyi by phenotype and 2
of these were found to contain genes for one or more component of the C2 toxin.
None of these isolates contained the genes for any of the major toxins. Of the 25
isolates studied from control horses 12 were phenotypically characteristic of the
Group III Clostridia, 2 of which contained the gene for component I of the C2 toxin.
A further 2 isolates contained genes for component II of the C2 toxin.
The bacteriophages encoding the toxin genes are pseudolysogenic and consequently
unstable and easily lost from the host cell. Sporulation, subculturing in the
laboratory and growth at 37°C can all predispose the bacterium to loss of the phage
(Eklund et al, 1987). The isolates studied required repeated subculturing to obtain
pure cultures. There are numerous problems involved in the culture of these
organisms due to the lack of a selective medium for Group III Clostridia and their
fastidious nature. They are also frequently overgrown by other bacteria present in the
gut. It is possible that some of the isolates obtained were producing BoNT/C or
contained the genes to enable them to do so in vivo but had lost the bacteriophage
carrying the BoNT/C gene by the time they were isolated in pure culture.
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Identification of the organisms produced is further complicated by the large numbers
of atypical organisms studied particularly in terms of the gene profiles. The reasons
for this are not known though horizontal transfer of genes between Clostridia has
been documented. Notably strains of C. butyricum producing the BoNT/E toxin have
been implicated in food-bome botulism (Zhou et al. 1993). Within the Group III
Clostridia strains of C. botulinum C and D have been shown to produce mosaic toxins
whose antigenicity is not consistent with either BoNT/C or BoNT/D (Moriishi et al.
1996).
The C2 toxin is produced by the majority of C. botulinum type C strains and some C.
botulinum type D strains. It is not known if the toxin is produced by C. novyi type A,
but the genes have been detected in a number of C. novyi type A strains. The C2
toxin gene is therefore used as a marker for Group III Clostridia. The genes for both
components of this binary toxin are located on the bacterial chromosome and are
therefore more stable then the phage-encoded toxin genes. The component I is
associated with enzymatic activity and the component II with binding to target cell
receptors. Many of the isolates studied were found to contain the genes for only one
of the components. It is not known if this is due to the loss of one of the genes or
from horizontal transfer of a single gene between organisms. It is also not known if
the strains in which only the component I gene is present are capable of producing an
active C2 toxin.
In all of the positive PCR results for the component I gene an unexpected number of
products and bands of atypical sizes were seen. Heterogeneity in the component II
104
gene has been identified (Kimura et al. 1998) and strains have been divided into three
groups based on differences in the molecular weight of the C2 toxin, thought to be
due to differences in the gene for the component II. The primers used to amplify the
component II gene had been shown to amplify DNA from all 3 groups (Kimura et al,
1998) though this study was based on a small number of reference strains.
The use of an immunomagnetic separation technique reduced the number of bacterial
colonies obtained from the culture of gastrointestinal contents but did not give pure
cultures ofGroup III Clostridia. The isolates obtained showed the same atypical toxin
gene profiles for their phenotype seen with the isolates obtained by traditional culture
methods. Two of the isolates that were positive for the BoNT/C gene by PGR
produced bands of an unexpected size and were found to produce detectable levels of
toxin by ELISA-based toxin assay. These isolates were subsequently lost in
subculture.
Due to the problems associated with culture and isolation of Group III Clostridia and
the risk of missing atypical isolates using this technique and the lack of availability
of the toxin assay to confirm the presence of BoNT/C in isolates giving atypical PCR
results, it was decided to concentrate on the molecular detection of toxin genes.
PCR detection of the BoNT/C gene in enrichment cultures of tissue and
gastrointestinal contents again produced products of unexpected sizes. The expected
product of the primary PCR reaction was a single product of 665bp with additional
products of 466bp, 424bp and 225bp arising from the nested PCR reaction. An 800bp
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PCR product was detected in many of the samples. Multiple bands between lOObp
and 1200bp were also detected in many samples. The reasons for this are not clear
though it is possible that it is due to heterogeneity in the BoNT/C gene sequence.
Cross-reactivity of the primers could explain the presence of unexpected products.
While the majority of bands sent for sequencing match the BoNT/C gene sequence in
BLAST, matches were also found for C. perfringens anaerobic sulphite reductase, B
subunit gene and for Drosophila melanogaster genes. None of these bands were
detected by Southern blotting using the probes designed from consensus sequences
of the BoNT/C products from gastrointestinal samples.
The BoNT/C gene was detected in 4 of the 7 horses with histopathologically
confirmed grass sickness by Southern blotting. None of the control horses were
found to contain the BoNT/C gene. This may be due to the small number of
genes/isolates in the GI tract and the small area sampled for culture. All of the
samples that gave a positive result by Southern blotting showed a banding pattern
consistent with the C. botulinum type C (MPRL 4564) used as a positive control and
product sizes were as expected with the primers used. Southern blotting also
appeared to enable the detection of bands present in the DNA extracts from
enrichment cultures that were invisible under uv light on agarose gels stained with
ethidium bromide.
Where the BoNT/C gene was found in equine samples, it was consistently detected
in the duodenal contents. In addition, the BoNT/C gene was detected in the rectal
contents of two of the animals in the study. Distribution of the toxin gene along the
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GI tract in acute cases may explain the neurological degeneration seen at most sites
along the gastrointestinal tract sampled in acute cases (Scholes et al. 1993; Doxey et
al. 1995). The detection of the BoNT/C gene in the pharynx sample may be a result
of cross-contamination during sample collection. The size of the pharynx was too
small to allow the outer part of the sample to be discarded as in other samples. Of the
13 enrichment cultures that tested positive for BoNT/C by PCR and Southern
blotting 9 were from overnight incubation and only 4 from 5 day incubation. This
may indicate the presence of free bacteriophage in the contents of the gastrointestinal
tract that is degraded during the incubation period.
The results obtained may provide further evidence of a link between C. botulinum
type C and equine grass sickness when combined with the serological data.
Significantly lower levels of IgG to both the surface antigens of Group III Clostridia
and to BoNT/C have been detected in horses with grass sickness compared to
controls (Hunter and Poxton, 2001). It is not known if this difference is due to the in
vivo neutralisation of the organism and toxin resulting in lower levels of antibodies
available for detection, or if the horses with grass sickness would have demonstrated
lower levels of IgG prior to the onset of the disease, allowing the proliferation and
toxin production of C. botulinum type C within the gastrointestinal tract. The
detection of significantly higher levels of IgA to BoNT/C within the gastrointestinal
tract of horses with grass sickness compared to controls suggests recent exposure to
the toxin in animals that develop the disease (Nunn et al, 2007).
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The detection of C2 toxin genes in control animals as well as those with grass
sickness may support the hypothesis that animals carry a Group III like organism
within the gut that either carries the phage or becomes infected with the phage within
the GI tract. The inability to isolate characteristic organisms and the detection of
toxin genes from whole gut enrichment cultures suggests that a molecular approach
is needed. The use of PCR for the detection of Group-Ill specific 16s rRNA or
similar genes would enable the detection of carriage of these organisms in both
affected and healthy horses.
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Chapter Four
Molecular Characterisation and detection of toxin genes of Group III
Clostridia
Due to the detection of isolates of Group III Clostridia containing genes for one or
more component of the C2 toxin and none of the defining major toxins, the following
work was carried out to investigate the toxin gene profiles of a variety of Group III
Clostridia from human, environmental and animal sources. Much of the material
presented in this chapter has been published (See Appendix)
4.1 Results
4.1.1 Investigation of Group III toxin genes by PCR
PCR detection of the novyi alpha toxin gene
All of the strains studied were found to be phenotypically similar and consistent with
the Group III Clostridia producing both lecithinase and lipase when grown on egg
yolk agar. All were microscopically identified as Gram positive or Gram variable
rods. Spores, if present, were large and sub-terminal. Twenty two out of forty strains
identified as C. novyi type A carried the alpha toxin gene (Table 4.1), as
demonstrated by the presence of a 260bp PCR product, using the Nov primers (Fig.
4.1). None of the strains identified as C. botulinum type C or type D were found to
carry the alpha toxin gene.
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PCR detection of the BoNT/C and BoNT/D genes
PCR with the Tox-384/Tox-850 primers produced a product of 466bp in one of the
strains identified as C. botulinum type C (NCTC 8548) demonstrating the presence of
the BoNT/C gene. The lack of PCR product in the other two type strains (NCTC
3732 and NCTC 10914) suggests that the phage carrying the BoNT/C gene has been
lost. These strains had previously been shown to be BoNT/C negative by use of a
specific ELISA for the direct detection of the toxin. None of the organisms identified
as C. novyi type A or C. botulinum type D were found to carry the BoNT/C gene by
PCR.
PCR with the ToxD primers produced a 497bp product from DNA of C. botulinum
type D strain (NCTC 8265) demonstrating the presence of the BoNT/D gene. None
of the organisms identified as C. novyi type A or C. botulinum type C were found to
be carrying the BoNT/D gene.
PCR detection of the C2 toxin genes
Thirty one of the strains carried the gene for the component I of the C2 toxin (Table
4.1), as demonstrated by the production of a 310bp product using the C2CI primers.
The C. botulinum type D strain (MPRL 3923) produced a PCR product of
approximately 650bp with the C2C1 primers (Fig 4.2). Sequence analysis of this
product showed it to match the sequence of the C2 toxin gene when entered into a
BLAST search.
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Eight of the strains produced a PCR product of 1049bp using the C2CII primers
indicating the presence of the gene for the component II of the C2 toxin.
Only five of the strains carried genes for both the CI and CII components of the C2
toxin; the C. botulinum type C strain (MPRL 4564) which produces the BoNT/C and
the non neurotoxin producing strain MPRL 2510; the C. botulinum type D strain
(MPRL 3923) and two of the strains identified as C. novyi type A (MPRL 2307 and
2534) both of which were found to be negative for the novyi alpha toxin gene by
PCR.
Ill
Toxin Profile By PCR
Lab No. Organism novyi a C2CI C2C1I BoNT/C BoNT/D
141 C. novyi type A-like - + - - -
465 C. novyi type A - + - - -
2306 C. novyi type A - + - - -
2307 C. novyi type A - + + - -
2510 C. botulinum type C - + + - -
2530 C. novyi type A + + - - -
2531 C. novyi type A + + - - -
2533 C. novyi type A - + - - -
2534 C. novyi type A - + + - -
2535 C. novyi type A - + - - -
2536 C. novyi type A + + - - -
3209 C. novyi type A + + - - -
3341 C. novyi type A - - - - -
3923 C. botulinum type D - + + - +
4540 C. novyi type A + + - - -
4541 C. novyi type A + + - - -
4545 C. novyi type A + + - - -
4547 C. novyi type A + + - - -
4548 C. novyi type A + + - - -
4549 C. novyi type A - + - - -
4550 C. novyi type A - - - - -
4551 C. novyi type A - + - - -
4552 C. novyi type A + - - - -
4553 C. novyi type A - - - - -
4554 C. novyi type A - + - - -
4556 C. novyi type A - - - - -
4557 C. novyi type A - - - - -
4558 C. novyi type A - + - - -
4559 C. novyi type A - - - - -
4561 C. novyi type A - + - - -
4562 C. novyi type A + + - - -
4563 C. novyi type A + + - - -
4564 C. botulinum type C - + + + -
4565 C. botulinum type C - + - - -
4566 C. novyi type A + + - - -
4567 C. novyi type A + + - - -
4568 C. novyi type A + + - - -
4569 C. novyi type A + + - - -
4570 C. novyi type A + - - - -
4571 C. novyi type A + + - - -
4572 C. novyi type A + - - - -
4573 C. novyi type A + - + - -
4574 C. novyi type A + - + - -
4575 C. novyi type A + - + - -
Table 4.1: Toxin gene profile of Group III Clostridia from the laboratory
collection.
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Figure 4.1 PCR detection of the major toxin genes. Lanes 1 and 8, 100bp
ladder; lanes 2 and 3, BoNT/C, strain 4564 and negative control; lanes 4 and
5 BoNT/D, strain 3929 and negative control and lanes 6 and 7 C. novyi a
toxin, strain 2307 and negative control.
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Figure 4.2 PCR detection of the C2 toxin genes. Lanes 1 and 10, 100bp
ladder; lanes 2-5, C2CI strains 4564, 3923, 2307 and negative control; lanes
6-9 C2CII strains 4565, 3923, 2307 and negative control.
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4.1.2 Investigation of the 16S rRNA gene in Group III Clostridia
All of the strains produced a PCR product of approximately 400bp with the 16S
primers (Fig 4.3) demonstrating the presence of the bacterial 16s ribosomal RNA
gene and the correct working of the primers.
A heteroduplex mobility assay was devised in order to detect any difference in the
sequence of the 16s rRNA gene within the Group III Clostridia in an attempt to
further identify or group them at a molecular level. Additional bands were seen when
this was carried out with duplexes between C. botulinum type C (strain 4564) and a
range of Clostridia (Fig 4.4) indicating possible difference between the DNA
sequence within a section of the gene. No additional bands were seen with duplexes
between C. botulinum type C (Strain 4564) and the other Group III Clostridia (Fig.
4.5) which suggests a greater degree of similarity in the gene sequence of the portion
of the 16s rRNA gene studied.
Sequence analysis of the 16s rRNA gene in Group III Clostridia
Sequence analysis of the purified PCR products confirmed that all sequences
matched the sequence of the 16S rRNA gene in BLAST. Sequence alignment of the
data obtained showed a high degree of homology between the sequences of the
Group III Clostridia tested (Fig 4.6), a lower degree of sequence homology was
observed between the gene sequences obtained from the unrelated Clostridia (Fig




Figure 4.3 PCR detection of the 16S rRNA gene. Lane 1, 100bpDNA ladder;
lane 2, MPRL 141; lane 3, MPRL 2307; lane 4, MPRL 2510; lane 5 MPRL
2530; lane 6, MPRL 3923; lane 7, MPRL 4550; lane 8, MPRL 4564; lane 9,
MPRL 4575; lane 10, negative control.
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Figure 4.4 Heteroduplex mobility assay of 16s rRNA PCR products. Lanes 1
and 20, 100bp ladder; lane 2, MPRL 4564; lane 3, MPRL 4564 and MPRL
2509; lane 4, MPRL 4564 and MPRL 2511; lane 5, MPRL 4564 and MPRL
2512; lane 6, MPRL 4564 and MPRL 2661; lane 7, MPRL 4564 and MPRL
2778; lane 8, MPRL 4564 and MPRL 3923; lane 9, MPRL 4564 and
MPRL2645; lane 10, MPRL 4564 and MPRL2591; lane 11, MPRL 4564 and
MPRL 4354; lane 12, MPRL 4564 and MPRL 4526; lane 13, MPRL 4564 and
MPRL 2618; lane 14, MPRL 4564 and MPRL 2528; lane 15, MPRL 4564 and
MPRL 2656; lane 16, MPRL 4564 and MPRL 2651; lane 17, MPRL 4564 and
MPRL 3271; lane 18 MPRL 4564 and MPRL 3573; lane 29, MPRL 4564 and
E. coli.
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Figure 4.5 Heteroduplex mobility assay of 16S rRNA PCR products. Lane 1,
100bp ladder; lane 2 MPRL 4564 and MPRL 141; lane 3, MPRL 4564 and
MPRL 2533; lane 4 MPRL 4564 and MPRL 3923; lane 5 MPRL 4564 and
MPRL 3209; lane 6, MPRL 4564 and MPRL 4545; lane 7, MPRL 4564 and
MPRL 4550; lane 8, MPRL 4564 and MPRL 4552; lane 9, MPRL 4564 and
MPRL 4558; lane 10, MPRL 4564 and MPRL 4565; lane 11, MPRL 4564 and
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CCRGCRC GT-TRTG-GTGGGCRCTCT—RRGGRGRCTGCCGGTGRCRRflCCGGRGGRHGGTGGGGRTGRCGTCRfl-GTCRTCfl TGGCCCTTRC GGCCTGGGCTRCRCRC-
CCRGCRC GTRTRTG-GTGGGCRCTCflTRRflGGRGRCTGCCGGTGflCRRRCCfiGGRRGHGRHGGGTGGfiGGflRTGfl-CTCGTCRRTCGflTCTfifiTCTflTGGCCCTTTRCTGGRCCTGGGCTRCRCRCT
CCHNCTCHTCGiRTRTGflGrGGGCRCTLRTRRRGGHGRCTGCCGGTGRCRRRCCGGHflGHRMUIGGGGRTGflCGTCRRTGTCflTCR TGGCCCTTTRCTGGNC-TGGGCTRCRCRC-
CTRCTRTTRRGT TflRGCRCTCTRRCGRGRCTGCCGCGGGTTRHCCGTGGRGGflRGGTGGGGRTGflCGTCRRR-TCRTCR TGCCCCTTRT GTCTRGGGCTRCRCRC-
CTRCTRTTflflGT TflflGCRCTCTRRCGflGRCTGCCGCGGTTRR—CGTGGRGGflRGGTGGGGRTGRCGTCRflfl-TCRTCfl TGCCCCTTRT GTCTRGGGCTRCRCRC-
CTRCCRTTRRGT TGRGCRCTCTRGCGRGRCTGCCTGGGTTRR--CCRGGflGGRRGGTGGGGflTGRCGTCRfiR-TCRTCR TGCCCCTTRT GTCTRGGGCTRCRCHC-
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Figure 4.6: Sequence alignment data obtained from Group III Clostridia using
the 16S primers. Blue text denotes 50% sequence homology and red text
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2509.1G5R —CCRGGCRGT CTCRTTnGnGTGCTCRnCTinR—TGGTnGCRRCTRnTnnCnn GGGTTGCGCTCGTTGCRGGnCTTn—
2GG1.1G5R -CKGGC8GT CTCGTTRGnGTGCTTRRCTTnn—TflGTnGCnnCTRRCnnTnn GGGTTGCGCTCGTTGCGGGnCTTR-
2G45.1G5R —CGCGGCRGT CTCGTTRGRGTGCTTRRCTTnR—TRGTnGCnnCTRflCnnTnfl GGGTTGCGCTCGTTGCGGGflCTTn-
3271.1G5R —CCRGGC8GT CTCGCTRGRGTGCTCRnCTmn—TGGTnGCRnCTRRCnnTnG GGGTTGCGCTCGTTGCGGGnCTTR-





Figure 4.7: Sequence alignment data obtained from Clostridia using the 16S
primers. Blue text denotes 50% sequence homology and red text denotes
90% sequence homology.
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4.1.3 Investigation of the rpoB gene in Group III Clostridia
All of the isolates tested were found to contain the rpoB gene producing a PCR
product between 300bp and 400bp demonstrating the presence of the bacterial rpoB
gene and the correct working of the primers. Heteroduplex mobility assay analysis of
the PCR products obtained from the Group III Clostridia tested revealed no difference
in the banding patterns obtained suggesting a high degree of homology in the region
of the gene tested.
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4.2 Discussion
Of the 40 strains previously identified as C. novyi type A by phenotypic methods,
only 22 were found to contain the C. novyi a toxin gene by PCR. It is possible that
this may be due to mis-match of the primers or heterogeneity in the sequence of the
C. novyi a toxin gene. Further sequencing of several a toxin genes would be required
to ensure that the primers are sensitive enough to detect the gene. The
pseudolysogenic relationship between the bacterial cell and bacteriophage is
inherently unstable. It is postulated that cycles of phage loss and re-infection occur in
nature. It is known that sub-culturing in the laboratory pre-disposes to phage loss as
does sporulation and culture of the organism at 37°C (Eklund et al, 1987). As many
of the strains tested have been part of the laboratory culture collection for many years
it is possible that they have lost the novyi a toxin gene at some point.
All of the strains tested that had been isolated from cases of infection in IDUs were
found to carry the C. novyi a toxin gene. All of these cases showed characteristic
pathology consistent with the action of the novyi a toxin. None of the isolates
obtained from IDU's appear to contain genes for both components of the C2 toxin
with the majority (64%) containing the gene for the enzymatic component (C2CI)
only, 27% containing the gene for the transport component (C2CII) only and one
isolate containing no C2 genes. It is not known if the genes are expressed by the
bacteria, reverse-transcriptase PCR would be necessary to determine this. It is
possible that the enzymatic component may play a part in the pathology and that the
transport component (C2CII) may not be required for the transport of the active
component into damaged cells.
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The distribution of toxin genes in animal and environmental samples appears to be
different with only 3 of the 14 strains tested carrying the novyi a toxin gene though
all of the isolates are phenotypically similar. The distribution of the C2 toxin genes is
similar in the animal and environmental isolates with 43% containing the gene for
the C2CI and none containing the gene for the C2CII. Only five strains were found to
contain the genes for both components of the C2 toxin, both the neurotoxin
producing C. botulinum type strains 4565 (type C) and 3923 (type D); one of the
BoNT/C-negative C. botulinum type C strains and two of the strains classed as C.
novyi type A that were found to be negative for the novyi a toxin. The origin of these
strains is unknown and it is possible that they are also C. botulinum strains that have
lost the neurotoxin gene.
Of the strains in which no toxin genes were detected, 5 were isolated from animals;
one from a hare with dysautonomia and four from horses, two of which had active
dysautonomia at the time of sampling. The other was isolated from a soil sample.
The C2 toxin genes are carried on the bacterial chromosome and the toxin is
produced by the majority of C. botulinum type C strains and by some C. botulinum
type D strains (Fujii et al, 1996; Kimura et al, 1998), though it had not been reported
as being produced by C. novyi type A. The presence of the genes for one or more
component of the C2 toxin gene in isolates may provide evidence of the horizontal
transfer of genetic material between Group III Clostridia in vivo. This further
demonstrates the close relationship between the Group III Clostridia and the difficulty
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in identifying organisms when the major toxin is not present. This close relationship
is also seen in the high degree of homology in the 16S rRNA gene as demonstrated
by sequence analysis of PCR products from the Group III Clostridia investigated,
compared with the lower degree of sequence homology between unrelated Clostridia.
It is possible that the low level of detection of the component II gene may be due to
sequence differences between the organisms. Heterogeneity in the component II gene
has been identified (Kimura et al, 1998) and strains have been divided into three
groups based on differences in the molecular weight of the C2 toxin, thought to be
due to differences in the gene for the component II. The published primers had been
shown to amplify the component II gene from all three groups but were found to
produce inconsistent results and were re-designed based on a published sequence
(Kimura et al, 1998). It is possible that the lack of detection is therefore due to
differences in the gene structure meaning that they are not detected by the primers. In
order to verify this more sequence data would be needed from several isolates.
The investigation of C2 toxin production in strains in which one or both of the C2
toxin gene components is required to establish whether these genes are no longer
present or whether the PCR is not sensitive enough to detect the differences in gene
sequences. This would require sequencing of several strains in order to produce
primers for reverse-transcriptase PCR. Antibodies for the direct detection of the CI
and CII components of the C2 toxin by dot blotting were investigated but were found
to be highly cross-reactive with a number of different Clostridia.
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It has been hypothesised that a common bacterial strain exists in nature and that its
pathogenicity is determined by the toxin it produces and therefore by the presence of
the specific converting phage (Eklund et al, 1974). There is therefore a question as
to whether the Group III Clostridia should be classified as separate species. The only
method of differentiating between the organisms relies on the production of the
major toxin that is carried on a bacteriophage. However, the bacteriophages are
pseudolysogenic and highly unstable. They are also potentially able to infect all three
species of Clostridia, effectively changing the identity of the cell they infect. It had
been thought that the detection of the minor toxins such as the C2 toxin could be
used to differentiate between C. botulinum and C. novyi strains, particularly those
that have lost the phage encoding the major toxin. However, this study has
demonstrated that the toxin gene profiles of these organisms are highly variable and
further demonstrates how closely related these organisms are.
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Chapter Five
Investigation into the prevalence of toxigenic Clostridia in seabirds
The techniques developed for the detection of botulinum toxin genes from GI
enrichment cultures were used to investigate the prevalence of botulinum neurotoxin
genes in sea birds and their potential as a reservoir for infection. The association
between the Fulmar and neonatal tetanus was also investigated in this chapter.
5.1 Results
5.1.1 Direct detection of BoNT/C in the gastrointestinal contents
and plasma of seabirds by ELISA
Of the ten samples tested for the presence of BoNT/C by ELISA, 5 were found to
contain detectable levels of the toxin (Table 5.1). Of these, two showed an increase
in the level of toxin detected over the 5 day incubation period of the enrichment
(B303427/1 and B303467). This indicated the presence of viable bacteria in the
sample that continued to produce neurotoxin. A decrease in the amount of toxin
detected over the five day culture period was seen in three of the samples
(B303534/2; B303427/4 and B303515/1). This suggested that viable cells were no
longer present in the sample or that any cells present were no longer producing
neurotoxin.
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Sample Number Sample type ELISA toxin (ng/ml)
Day 0 Day 5
B303427/1 GI contents (herring gull) 1.8 9.8
B303427/2 GI contents (herring gull) <0.8 <0.8
B303467 GI contents (gannet) 1.4 6.0
B303467b Plasma (gannet) <0.8 <0.8
B303515/1 GI contents (herring gull) 4.0 1.2
B303515/2 GI contents (herring gull) <0.8 <0.8
B303427/3 Plasma (herring gull) <0.8 <0.8
B303427/4 Plasma (herring gull) 1.07 <0.8
B303534/2 GI contents (herring gull) 4.0 3.0
B303534/2b Plasma (herring gull) <0.8 <0.8
Table 5.1: Direct detection of BoNT/C by ELISA in gastrointestinal contents
and plasma samples from seabirds.
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5.1.2 Detection of botulinum neurotoxin types A-E genes by PCR
Detection of the BoNT/A, BoNT/B and BoNT/E genes by multiplex PCR
The multiplex PCR assay used was found to give inconsistent results when all three
primer sets were used with a high incidence of false negatives in the detection of the
BoNT/E gene. It was therefore decided to use the BoNT/A and BoNT/B primer sets
only in the multiplex PCR reaction and perform the PCR for the detection of the
BoNT/E gene separately.
PCR with the multiplex primers produced a 782bp PCR product with DNA from the
C. botulinum type A strain (MPRL 2509) (Figure 5.1) demonstrating the presence of
the BoNT/A gene. Seven of the 20 DNA samples taken from the overnight culture of
the gastrointestinal contents of seabirds also produced a 782bp PCR product
indicating the presence of the BoNT/A gene within the GI contents of those birds
(Table 5.2).
A PCR product of 205bp was amplified from the C. botulinum type B strain (MPRL
2511) (Figure 5.1) demonstrating the presence of the BoNT/B gene. Eight of the 20
DNA extracts from enrichment cultures were also found to contain the BoNT/B gene
(Table 5.2).
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Figure 5.1: Detection of the BoNT/A and BoNT/B toxin genes by PCR. Lane
1, 100bp DNA ladder; lane 2, B303427/1; lane 3, B303427/2; lane 4, B303
534/2; lane 5, B303467; lane 6, B303515/1; lane 7, B303515/2; lane 8,
B303853/1; lane 9, B303853/2; lane 10, B303853/3; lane 11, B303853/4;
lane 12, B303855/1; lane 13, B303855/2; lane 14, B303855/3; lane 15,
B303855/4; lane 16, B303855/5; lane 17, B303855/6; lane 18, B304150; lane
19, B301155a; lane 20, C. botulinum type A (MPRL 2509) and C. botulinum
type B (MPRL 2511).
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PCR results
Sample BoNT/A BoNT/B BoNT/C BoNT/D BoNT/E
B303427/1 + - + - -
B303427/2 + -
B303467 + + + +
B303515/1 + - - -
B303515/2 + +
B303534/2 - -
B303853/1 + + + -
B303853/2 + - + -
B303853/3 + -
B303853/4 - +
B303855/1 + + - +
B303855/2 -








Table 5.2: PCR detection of the BoNT/E gene
Toxin gene profiles of enrichment cultures from the gastrointestinal contents
of seabirds.
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PCR with the BoNT/E primers produced a 389bp PCR product with DNA from the
C. botulinum type E strain (MPRL 2512) (Figure 5.2) demonstrating the presence of
the BoNT/E gene. Six of the 20 DNA samples taken from the overnight culture of
the gastrointestinal contents of seabirds also produced a 389bp PCR product
indicating the presence of the BoNT/E gene within the GI contents of those birds
(Table 5.2).
PCR detection of the BoNT/C gene
PCR with the Tox384/Tox850 primers produced a 466bp product with DNA from
seven of the twenty enrichment cultures indicating the presence of the BoNT/C gene.
No additional positive results were seen using the Tox625/Tox 1049 primer pairs or
using the nested PCR for the detection of the BoNT/C gene.
PCR detection of the BoNT/D gene
PCR with the DS primers produced a 497bp product from DNA of C. botulinum type
D demonstrating the presence of the BoNT/D gene. None of the DNA extracts from
enrichment cultures were found to contain the gene.
Four of the enrichment cultures were found to contain two neurotoxin genes by PCR
(B303427/1B303515/2, B303853/2 and B303855/3). Two of the birds tested positive
for three neurotoxin genes (B303853/1 and B303855/1) and one bird, B303467, was
found to contain the genes for 4 of the 5 neurotoxins.
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5.1.3 Detection of the C2 toxin genes and novyi alpha toxin gene
by PCR
PCR with the C2CI primer gave a band of approximately 300bp in seventeen of the
twenty enrichment cultures (Fig 5.2) (Table 5.3) indicating the presence of the gene
for the enzymatic component of the C2 toxin. Additional bands of varying sizes were
observed in some of the samples though it is not clear what these bands represent.
None of the enrichment cultures produced any PCR products with the C2CII primers
(Fig 5.2) suggesting that none of the DNA extracts contain the gene for the transport
component of the C2 toxin.
PCR with the Nov primers produced a 260bp PCR product with DNA from C. novyi
type A (MPRL 2530) demonstrating the presence of the gene for the novyi alpha
toxin. None of the enrichment cultures were found to contain the novyi alpha toxin
gene.
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Figure 5.2: PCR detection of the C2 toxin genes. Lane 1, lOObp DNA ladder; lane 2,
B303427/1 (C2CI); lane 3, B303427/1 (C2CII); lane 4, B303427/2 (C2CI); lane 5,
B303427/2 (C2CII); lane 6, B303467 (C2CI); lane 7, B303467(C2C1I); lane 8,
B303515/1 (C2CI); lane9, B303515/1 (C2CII); lane 10, B303515/2 (C2CI); lane 11,
B303515/2 (C2CII); lane 12, B303534/2 (C2CI); lane 13, B303534/2 (C2CII); lane 14,
B303853/1 (C2CI); lane 15, B303853/1 (C2CII); lane 16, B303853/2 (C2CI); lane 17,
B303853/2 (C2CII); lane 18, B303853/3 (C2CI); lane 19, B303853/3 (C2CII); lane 20,
B303853/4 (C2CI); lane 21, B303853/4 (C2CII); lane 22, B303855/1 (C2CI); lane 23,
B303855/1 (C2CII); lane 24, B303855/2 (C2CI); lane 25, B303855/2 (C2CII); lane 26,
B303855/3 (C2CI); lane 27, B303855/3 (C2CII); lane 28, B303855/4 (C2CI); lane 29,
B303855/4 (C2CII); lane 30, B303855/5 (C2CI); lane 31, B303855/5 (C2CII); lane 32,
B303855/6 (C2CI); lane 33, B303855/6 (C2CII); lane 34, B304150 (C2CI); lane 35,
B304150 (C2CII); lane 36, B301 155a (C2CI); lane 37, B301155a (C2CII); lane 38,

























Table 5.3: Group III clostridial toxin gene profile of enrichment cultures from
the gastrointestinal contents of seabirds.
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5.1.4 Detection of Clostridium tetani in soil samples from St. Kilda
and Fulmar oil samples.
Isolation of Clostridium tetani
All four of the environmental / soil samples collected from St. Kilda were found to
contain C. tetani-like organisms as demonstrated by the presence of a fine, swarming
growth on blood agar. Sub-culture of organisms picked from the leading edge of the
swarming colony produce discrete colonies when plated onto 4% agar. Colonies
were faintly haemolytic and microscopically resembled C. tetani with the
characteristic 'drumstick spores' visible in older cultures.
None of the Fulmar oil samples were found to contain organisms resembling
C. tetani by culture on blood agar. The majority of the Fulmar samples tested
contained no viable organisms. The three that were found to contain viable
organisms did not appear to be pure samples of Fulmar oil but seemed to be
contaminated with stomach contents.
Culture of a laboratory strain of C. tetani on blood agar containing a filter paper disc
soaked in Fulmar oil produced the typical fine swarming growth. No zone of
inhibition was seen around the filter paper and growth of C. tetani was observed over
the surface of the disc. This suggests that Fulmar oil is not inhibitory to the growth of
C. tetani.
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PCR detection of the C. tetani neurotoxin gene
PCR with the Tet primers produced a PCR product of around 1400bp with DNA
from C. tetani (MPRL 2777) demonstrating the presence of the fragment C of the
tetanus neurotoxin. All four of the soil enrichment cultures were found to contain the
Tetanus neurotoxin gene. None of the Fulmar oil samples produced any visible PCR




The direct detection of type BoNT/C in samples B303427/1 and B303467 supports
the diagnosis of botulism as the cause of death of these birds. The increase in levels
of toxin detected indicates the presence of viable bacteria within the gut contents that
are producing toxin. The decrease in the amount of toxin detected following 5 day
incubation in samples B303534/2, B303427/4 and B303515/1 suggests that either
pre-formed toxin alone is present which is typical of classical food-borne botulism,
or that any C. Botulinum cells present are no longer producing neurotoxin.
Both of the samples that showed an increase in the amount of neurotoxin detected
were found to contain the BoNT/C gene by PCR. The gene was not detected in the
gut contents of the birds which showed a decrease in the amount of toxin produced
supporting the results of the toxin assay. An additional 5 samples were found to
contain the BoNT/C gene. The BoNT/D was not detected in any of the samples
though the other neurotoxins were found in approximately equal numbers with
BoNT/E found in 6 samples, BoNT/A and BoNT/C found in 7 samples and BoNT/B
in 8 samples.
Type C and D botulinum are the most common avian forms of the disease with type
C being a major cause of mortality in British gulls. The presence of type A
neurotoxin and subsequent culture of the organism from the digestive tract of a gull
has been documented (Ortiz and Smith, 1994) though this was considered unusual as
C. botulinum is not a normal component of the gut flora of birds. The detection of
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neurotoxin genes in the gut contents of birds in this study indicates the presence of
the organism in the gut and not the presence of pre-formed toxin only. It is probable
• that these organisms had been recently ingested by the birds though the source of
them is unknown. Previous studies have suggested that C. botulinum type B is the
most common strain in British coastal sediments. C. botulinum type B has also been
shown to be the predominant strain found in seawater fish and coastal sediments with
type A and type E also present though in lower numbers (Fach et al, 2002).
It is apparent that C. botulinum can be carried by seabirds and the presence of
neurotoxin genes in the gut contents suggests that the faeces of seabirds may be a
source of disease. Many birds appear to be carrying more than one strain of C.
botulinum. The majority of birds investigated in this study were herring gulls and this
may reflect the feeding behaviour patterns of the birds. The cormorant investigated in
this study was only found to contain the BoNT/E gene. All of the samples used in
this study had come from birds with suspected or confirmed botulism and therefore
the results may not be representative of the seabird population as no healthy controls
were available for comparison.
One of the samples of leeches tested positive for the BoNT/C gene however they are
unlikely to be the source of the infection and as the bacteria have not been found to
be systemic it is thought that this represents contamination of the sample.
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The high incidence of the C2 toxin seen in the birds samples is unexpected. The C2
toxin genes have been found to be prevalent in soil and environmental samples and
may just represent exposure to soil.
All of the soil samples from St. Kilda were found to contain C. tetani by both culture
methods and PCR detection of the gene for Fragment C of the neurotoxin. All of the
Fulmar oil samples were found to be sterile though it does not appear to be inhibitory
to the growth of C. tetani.
From this study it seems that the Fulmar oil itself does not appear to have been the
source of the tetanus spores that gave such a high incidence of neonatal tetanus on
the island. It is likely that the oil was either contaminated during collection or storage
or that the umbilicus became contaminated due to a combination of the living
conditions and the highly secretive midwifery practices. Fulmar oil is a sticky
substance and its presence over the wound site may have increased the risk of





6.1 Isolation and Characterisation of Group III Clostridia from equine
gastrointestinal contents
This thesis has further investigated the hypothesis that equine grass sickness is
caused by toxicoinfection with C. botulinum type C and has investigated methods for
the isolation and detection of pathogenic Clostridia and the characterisation of Group
III Clostridia by molecular methods.
While the aetiology of equine grass sickness remains unknown, epidemiological
studies suggest an infectious aetiology (Wood et al, 1998). The pathology of the
disease suggests the involvement of a neurotoxin with the characteristic neuronal
degeneration thought to be the primary event in the disease. Toxicoinfection with C.
botulinum type C has been proposed as the likely cause of grass sickness. The
previous detection of Group Ill-like organisms from the GI tract of horse with grass
sickness and the direct detection of BoNT/C in the GI tract combined with the
serological studies demonstrating significantly lower levels of antibodies to the
surface antigens of Group III Clostridia and to BoNT/C demonstrates an association
between C. botulinum type C and grass sickness (Hunter et al 1999: Hunter and
Poxton, 2001).
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Traditional culture methods for the isolation of Group III Clostridia, in particular C.
botulinum type C, from the GI tracts of horse with grass sickness were investigated
during the course of this thesis. Culture work was hampered by the lack of a selective
medium for isolation of the Group III Clostridia. A selection of both liquid and solid
media were investigated to optimise the recovery of, and toxin production by, C.
botulinum type C. Overgrowth of Group III Clostridia by other organisms in the GI
tract remained a problem due to the fastidious nature of these organisms and their
slow growth rate. This was further compounded by the increased anaerobic bacterial
content of the gastrointestinal contents of horses with grass sickness (Garrett et al
2002). The detection and isolation of Group III Clostridia from mixed cultures was
further hampered by the potential loss of the typical colony morphology. When
grown in a mixed faecal culture, the type strain of C. botulinum type C was not
consistently found to produce both the lipase effect and lecithinase on egg yolk agar.
These characteristics returned upon repeated subculture to obtain a pure culture. It
was therefore decided to isolate and further investigate colonies positive for lipase
only or lecithinase only from the GI contents of horse with grass sickness as well as
those resembling 'typical' Group III Clostridia.
Group Ill-like organisms putatively identified as such by colony morphology and
GLC profile were isolated from horses with grass sickness, their co-grazers and
control horses, though none of the isolates were found to contain the genes for the
species-defining major toxins. It is possible that equine grass sickness may result
from the conversion of a non-toxigenic organism in the GI tract by the introduction
of the converting phage from an external source. The prevalence of Group III
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Clostridia in the GI tract of the equine population is not known, though this study
suggests that non toxin-producing organisms may be present in the GI tracts of
healthy horses with isolates containing the genes for one or both components of the
C2 toxin found in the gastrointestinal contents of horses with grass sickness, their co-
grazers and control horses. Group III Clostridia have also been isolated from soil
samples which may provide a reservoir for infection (Nakamura et al 1978).
Due to the problems associated with the culture and isolation of Group III Clostridia,
it was decided to focus on molecular methods for the detection of toxin genes within
the gastrointestinal tract and the characterisation of isolates. PCR detection of the
BoNT/C gene yielded multiple products of atypical sizes with multiple bands
between lOObp and 800bp present in many of the samples. It is not known if this is
due to cross-reactivity with the primers or due to non-specific binding to the primers
and subsequent amplification. A Southern blotting methodology was developed and
used to detect the BoNT/C gene in whole gut enrichment cultures. A selection of the
PCR products obtained from the gastrointestinal enrichment samples were
sequenced. Those that matched the sequence of the BoNT/C in a BLAST search
were used to obtain a consensus sequence. Two probes for Southern blotting were
then ordered based on these sequences.
In this preliminary study, the BoNT/C gene was detected in four of the seven horses
with confirmed grass sickness and in none of the control animals by Southern
blotting. The BoNT/C gene was detected in enrichment cultures of two or more sites
in all four animals. This is consistent with the pattern of neuronal degeneration seen
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along the length of the gastrointestinal tract in horses with acute grass sickness
(Scholes et al. 1993) though it is not known if the toxin was produced at these sites.
The detection of the toxin gene itself within the gastrointestinal tract of horse with
acute grass sickness supports the hypothesis that grass sickness is caused by a
toxicoinfection with C. botulinum type C with locally produced toxin causing the
neuropathology that is characteristic of the disease.
The BoNT/C gene was detected in the ileum of only one of the horses tested. The
neuronal damage seen in grass sickness is usually severe and extensive in the ileum
(Scholes et al. 1993) and it has been proposed that, in acute cases, the animals are
exposed to large amounts of toxin in the ileum and jejunum in a short period of time.
It would therefore be expected that the BoNT/C gene would be present in the ileal
contents of all of the animals with confirmed acute grass sickness. The absence may
reflect the small sample size used in this study or the degradation of the toxin gene
prior to the euthanasia of the animal or during the enrichment culture. The detection
of IgA to BoNT/C in the GI tracts of horses with grass sickness (Nunn et al, 2007)
suggests exposure to the toxin prior to the onset of symptoms in horses with acute
grass sickness. It is possible that the toxigenic organisms or free bacteriophages in
the GI tract are no longer present in the gut at the time of sampling.
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6.2 Molecular characterisation and detection of toxin genes of Group III
Clostridia
The detection of isolates from the gastrointestinal contents of horses containing
genes for one or both of the components of the C2 toxin but none of the defining
major toxins led to a study on the distribution of toxin genes in a selection of
laboratory isolates of C. botulinum types C and D and C. novyi type A.
The C2 toxin is documented as being produced by the majority of C. botulinum type
C strains and by some type D strains (Fujii et al, 1996; Kimura et al, 1998). Its
presence in C. novyi type A has not been reported. The C2 toxin is a binary ADP-
ribosylating toxin composed of an enzymatic portion (C2CI) and a binding portion
(C2CII).
This study found a high incidence of the gene for the C2CI enzymatic component in
isolates from a variety of sources, both clinical and environmental but a much lower
incidence of the gene for the C2CII binding component. Two of the three C.
botulinum type C strains and the C. botulinum type D strain tested were found to
contain the genes for both components of the C2 toxin as expected based on the
current literature. One of the three C. botulinum type C strains was found to contain
the gene for the C2CI only. It is not clear if the C2CII gene has been lost in this
strain or if sequence heterogeneity within the C2CII gene is responsible for a mis¬
match with the primers. The primers used to identify the C2CII gene had been shown
to amplify DNA from all three groups identified based upon the molecular weight of
the C2 toxin produced (Kimura et al, 1998) though this was based upon a small
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sample size so it is possible that there are further sequence variations within the
C2CII gene.
Of the 40 strains identified as C. novyi type A in the laboratory culture collection,
only 22 were found to contain the C. novyi a toxin gene by PCR and 6 strains were
found to contain none of the toxin genes investigated. All of the clinical isolates
obtained from the outbreak of C. novyi wound infections in injecting drug users were
found to contain the C. novyi a toxin gene which is consistent with the pathology of
the disease.
Though the C2 toxin has not been previously reported in C. novyi type A, this study
found that 2 of the 40 strains tested contained the genes for both components of the
C2 toxin and 30 of the 40 strains tested contained the genes for one of the
components of the C2 toxin with the enzymatic component found in the majority of
strains. It is not known if these genes are being expressed by the bacteria. There is
no evidence that the C2CI alone has a role in pathogenesis though it is possible that it
may be able to enter damaged cells independent of the C2CII binding component and
add to the pathology of disease. The C2 toxin has been implicated in disease in
botulism in broiler chickens and horses (Ohishi and DasGupta, 1987; Kinde et al,
1991).
This further demonstrates the close relationship between these organisms and
complicates the identification of the Group III Clostridia to species level and the
characterisation of isolates in which the major toxin gene has been lost. C. botulinum
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type C and D are considered to be separate species based on a 1% sequence
divergence of the 16S rRNA gene (Collins and East, 1998) and C. novyi is
considered to be a separate species based upon a 2% sequence divergence within the
16S rRNA gene. The Group III Clostridia can only be identified to species level by
the detection of the major toxin. This thesis has highlighted the problems in
identifying bacteria based upon the detection of a toxin. The species-defining toxins
are carried on pseudolysogenic bacteriophages. The phage-host relationship is
unstable and the phages are readily lost upon sub-culture. In the absence of the major
toxin, these bacterial strains are indistinguishable from each other by basic culture
and PCR methodologies. Given the high degree of sequence heterogeneity seen in
clostridial genes, it is questionable whether a 1-2% sequence divergence is enough to
be able to class these organisms as separate species, particularly when the
bacteriophages that carry the species-defining toxins are potentially able to infect all
three species ofGroup III Clostridia, changing the identity of the cell they infect.
It has been proposed that there exists a common, non-toxigenic, strain and that its
pathogenicity is determined by the toxin it produces (Eklund and Poysky, 1974). The
results obtained in this thesis support the hypothesis that the Group III Clostridia
cannot be defined to a species level without the detection of the major toxin and that
there is not sufficient difference between C. botulinum types C and D and C. novyi




6.3 Investigation into the prevalence of toxigenic Clostridia in seabirds
This thesis also applied the techniques developed for the detection of toxin genes in
Clostridia to investigate the distribution of clostridial neurotoxin genes in seabirds.
Outbreaks of botulism occur frequently in birds and though they are susceptible to all
types of botulinum toxin, type C botulism is responsible for the majority of cases
(Lamanna, 1987). This study found detectable levels BoNT/C in 4 of the 6 samples
of gastrointestinal contents of seabirds found dead with suspected botulism which is
consistent with the published observations. Two of the samples showed an increase
in the amount of toxin detected over the 5 day incubation period suggesting the
presence of viable bacteria within the gut contents that are actively producing toxin.
This was confirmed by the PCR detection of the BoNT/C gene. In this study 8 of the
20 samples investigated were found to contain the gene for BoNT/B, 7 samples were
found to contain the gene for BoNT/C and no samples were found to contain the
gene for BoNT/D. Spores of C. botulinum types B, C and D were found in 63% of
landfill sites (Ortiz and Smith 1994) which is consistent with the results obtained
here for BoNT/B and BoNT/C.
This study detected the gene for BoNT/A in 7 of the 40 samples tested and the gene
for BoNT/E in 6 of the samples. The presence of type A neurotoxin from the
digestive tract of a gull has been previously reported but was considered unusual
(Ortiz and Smith, 1994). This study suggests that the carriage of C. botulinum by
seabirds may be more common than previously thought though all of the samples
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used in this study were from birds with suspected or confirmed botulism and so may
not be representative of the wider population.
The detection of a range of clostridial neurotoxin genes in the GI contents of seabirds
confirms the presence of toxin-producing organisms in the GI tract of birds. This
suggests that seabirds are able to act as a source of botulism and may be responsible
for the contamination of environmental sites with spores of C. botulinum. The source
of these organisms is not clear though C. botulinum type B has been shown to be the
predominant strain in seawater fish and coastal sediments with C. botulinum types A
and E also present (Fach et al, 2002).
Neonatal tetanus remains the most common form of the disease worldwide and was
thought to be a contributory factor in the evacuation of the island of St Kilda in 1930,
due largely to the decline in the population. This high incidence of the disease was
thought to be due to the practice of anointing the umbilicus of newborn babies with
oil collected from the Fulmar.
This study suggests that Fulmar oil is not a source of tetanus. All of the Fulmar oil
samples tested in this study were found to be sterile, though the oil itself was not
found to be inhibitory to the growth of C. tetani. The gene for the tetanus toxin was
found in all soil samples collected from St. Kilda as expected given the worldwide
distribution of the organism in soil. It is possible that the Fulmar oil was
contaminated with this soil-borne organism during collection or storage. We
148
conclude that the general living conditions were the more likely cause of the disease
though the fulmar oil may have contributed to the development of an anaerobic
environment within the wound site or simply be preventing the drying out and
healing of the area.
6.4 Conclusions and Further work
The aetiology of equine grass sickness remains unknown though epidemiological
studies suggest that grass sickness may have an infectious aetiology. The pathology
of the disease suggests a toxic aetiology. Toxicoinfection with C. botulinum type C
has been suggested as a cause of the disease and one which fits both of these criteria.
The detection of BoNT/C and BoNT/C-producing organisms in the gastrointestinal
tract of horses with grass sickness demonstrated a strong association between C.
botulinum type C and the disease. Serological studies have provided further evidence
of a link between C. botulinum type C and grass sickness. Horses with grass sickness
were found to have significantly lower levels of IgG to both surface antigens and
BoNT/C (Hunter and Poxton, 2001). This may be due to the in vivo neutralisation of
the organism and toxin resulting in a lower level of IgG available for detection or it
may be that lower levels of IgG are a risk factor for the development of the disease
with low antibody levels to the surface antigens allowing the proliferation of the
bacteria within the gastrointestinal tract. The detection of IgA to BoNT/C in horses
with grass sickness confirms recent exposure to the toxin, and in acute cases this may
be prior to the onset of gastrointestinal stasis.
149
The detection of the BoNT/C gene in a variety of sites along the gastrointestinal tract
of horses with confirmed grass sickness further demonstrates a link between C.
botulinum type C and grass sickness and provides evidence of the potential ability for
toxin production within the gastrointestinal tract consistent with a toxicoinfection.
The low level of detection of the BoNT/C gene in the ileal contents may further
support the serological data suggesting exposure to the toxin prior to the onset of
clinical symptoms and the theory that acute grass sickness is caused by exposure to
high levels of toxin over a short period of time.
Further work is required to confirm the identity of the genes identified as BoNT/C by
Southern blotting in this study by sequencing. Additionally RT-PCR to investigate
toxin production within the gastrointestinal tract may provide further evidence of a
toxicoinfection. At present the prevalence of Group III Clostridia within the
gastrointestinal tract of the equine population is not known. This study suggests that
non-toxigenic Group III organisms may be present in healthy horses as well as those
with grass sickness but sequencing of the C2 toxin genes identified by PCR would be
required to confirm this. The source of C. botnlinum should be established. If, as has
been suggested, grass sickness results from the conversion of a non-toxigenic
organism within the gastrointestinal tract by the introduction of the converting phage
then the source of the phage needs to be established. Investigation of pasture for the
presence of Group III Clostridia or the converting phages should determine whether
there is an environmental reservoir. The molecular methods developed in this thesis
form the basis for the identification of Group III Clostridia and the major toxin genes
without the need to culture viable, toxigenic organisms.
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This thesis has also highlighted the difficulties in identifying the Group III Clostridia
to species level when the species-defining toxin is not present. Further sequencing of
a large number of Group III Clostridia may determine whether they are different
enough to be considered separate species in the absence of the major toxin. Further
investigation into the carriage of the C2 toxin genes by these organisms is needed to
determine how widespread the carriage of this toxin is. In particular, investigation of
the primers used to detect the C2CII gene is required to eliminate the possibility of
false negatives due to sequence heterogeneity. Confirmation of PCR products by
sequencing is needed, particularly in strains carrying the gene for only one
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A PCR approach to determine the distribution of
toxin genes in closely related Clostridium species:
Clostridium botuiinum type C and D neurotoxins
and C2 toxin, and Clostridium novyi a toxin
Ann Heffron and Ian R. Poxton
Medical Microbiology, Centre for Infectious Diseases, University of Edinburgh College of
Medicine and Veterinary Medicine, The Chancellor's Building, 49 Little France Crescent,
Edinburgh EH 16 4SB, UK
The closely related Clostridium novyi and Clostridium botuiinum types C and D are of current
interest because of their association with serious infections in injecting drug users (C. novyi type A)
and equine and feline dysautonomias (C. botuiinum types C/D). The species are defined by the
major toxins they produce: the a toxin of C. novyi, and the type C and D neurotoxins of C. botuiinum
(BoNT/C and BoNT/D). The other major toxin produced by this group, and previously thought to be
restricted to the botuiinum types, is the chromosomally encoded C2 - a binary toxin consisting
of two components, I and II. In the current study 44 of these Clostridia from the authors' culture
collection were investigated - most of which had been identified previously by conventional
biochemical tests as 'C. novyi type A'. The aim was to check the distribution of toxin genes by PCR
to see if the identities were consistent with the genes carried, and to ascertain if the C2 gene was
only found in authentic C. botuiinum strains. Several combinations of the species-defining
genes and the two components of the C2 genes were detected. Only the authentic BoNT/C- and
BoNT/D-positive C. botuiinum strains and one of two non-neurotoxic variants of type C carried
genes for both components of the C2 toxin. Of the remaining 40 C. novyi type A-like strains, the
gene for the a toxin was found in 22, with 19 of these also possessing the gene for component I (1 6)
or component II (3) but not both. In the a toxin-negative strains (22), both of the C2 genes were
detected in 5 strains (3 C. botuiinum), with component I in 11 strains and neither gene in 6 strains.
INTRODUCTION
_ lostridium botuiinum type C and D (group III C.
■ otulinum) and the non-neurotoxigenic Clostridium novyi
vpe A are phenotypically similar and cannot be distin-
uished by traditional methods of culture or biochemical
roperties - including GLC fatty acid profiles (Hunter &
oxton, 2002). Immunologically they share many cross-
eactive surface antigens (Poxton & Byn,e, 1984).
"dentification of this group of organisms to the species
level is by the detection of the major toxin they produce: the
ootulinum neurotoxin C (BoNT/C) or D (BoNT/D) for C.
botuiinum and the a toxin for C. novyi. Traditionally this was
done by observing their lethal effects in animal models -
usually with specific neutralization by anti-toxin, and this is
still the only standard method for definitive identification of
C. botuiinum types.
The genes encoding the major toxin of this group of species
are carried on pseudolysogenic bacteriophages and the host-
phage relationship is unstable. The phage is readily lost
Abbreviation: IDU, injecting drug user.
during subculture and sporulation, and it is thought that
a cycle of phage loss and reinfection occurs in vivo.
Interconversion of toxin types also occurs between type C
and type D strains, and C. novyi type A. Furthermore, non-
toxigenic strains can be converted to type C or D or C. novyi
typeA by infection with the converting phages. Infection with
one phage confers immunity to the other phage suggesting
that the two.phages are closely related (Sunagawa & Inoue,
1991, 1992; Eklund et al, 1974; Hunter & Poxton, 2002).
The group III C. botuiinum members also produce a binary
ADP-ribosylating cytotoxin, the C2 toxin. This consists of
two separate components: the enzymic component, C2I,
and the transport component, C2II (Ohishi et al. 1980). The
genes for this toxin are located on the bacterial chromosome
and are produced by the majority of type C and some type D
strains (Fujii et al., 1996; Kimura etal, 1998). It is produced
during sporulation and may form part of the spore coat
(Nakamura et al., 1978).
C. botuiinum C and D are well known for causing botulism
in animals, particularly in birds, but not in humans
(Hatheway, 1995). C. novyi is recognized as a rare cause
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of wound and soft tissue infections in humans, classically
war wounds, and in farm animals, but the species has been
rarely encountered in clinical medicine over the past
50 years (Poxton, 2005). However, recently, awareness of
these organisms has increased: C. novyi has been encoun¬
tered in lethal infections in injecting drug users (IDUs)
(McGuigan et al., 2002), and G botulinum C and possibly D
has been identified as the probable aetiological agent of
equine dysautonomia/equine grass sickness (Hunter et al.,
1999; McCarthy et al., 2004) and of feline dysautonomia/
Key-Gaskell syndrome (Nunn et al., 2004) - both
characterized by damage occurring to the autonomic
nervous system - as revealed by histopathology.
In preliminary studies to develop PCR methods to detect the
genes that encode the toxins one or both components of the
C2 toxin genes were detected in some isolates previously
identified as C. novyi type A. As this cytotoxin may have
an important role in the pathogenesis of the conditions
described above, it prompted us to examine our laboratory
collection of C. novyi and related strains, previously
identified by a range of phenotypic characteristics, for the
presence of genes encoding the C2 toxin as well as the
characteristic major toxins of the group: the neurotoxins
BoNT/C and BoNT/D, and the C. novyi a toxin.
METHODS
Bacterial strains and culture. A total of 44 strains from our lyo-
philized culture collection were investigated in this study and are
listed in Table 1. The strains included 40 labelled C. novyi type A or
C. novyr-like, together with 1 BoNT/C-positive and 1 BoNT/D-posi-
tive C. botulinum strain and 2 BoNT/C-negative C. botulinum type
C strains. These BoNT/C-negative stains had been considered neuro-
toxigenic when originally deposited in the National Collection of
Type Cultures. It is unclear how all the strains had been identified as
they were collected over 40 years. All had been identified by R.
Brown utilizing biochemical reactions, including the detection of
fatty acid end products by GC, since about 1977 and the identifica¬
tion keys used are described in Collee et al. (1996).
All strains were cultured in 5 ml anaerobic identification medium
broth (Brown et al., 1996) with cooked meat particles and incubated
under anaerobic conditions (Mark III or MACS Anaerobic
Workstations, Don Whitley Scientific) at 37 C for 24 h and
subcultured onto Fastidious Anaerobe Agar (LabM) supplemented
with 10% egg yolk emulsion (Oxoid) for overnight incubation.
Template preparation. Ten large colonies were picked from each
plate and emulsified in 100 pi 5% suspension Chelex 100 (Bio-Rad)
following the method of de Lamballerie et al. (1992). Samples were
heated at 100 C for 10 min to release DNA and centrifuged at
1000 g for 5 min. A volume of 5 pi each supernatant was used as
the template in the PCR mix.
DNA amplification. PCR was performed in a reaction volume of
50 pi containing 1 x REDTaq PCR buffer (Sigma), 1.5 mM MgCl2
(3.75 mM for BoNT/C), 0.2 mM dNTP mixture, 2 U REDTaq
DNA polymerase, 10 pmol each primer and 5 pi each DNA tem¬
plate. All primers were synthesized by MWG Biotech (http://www.
mwg-biotech.com) and their sequences and reference source are
detailed in Table 2. All amplification reactions were carried out in a
PCR thermocycler (Techne TC-412). Cycling conditions are given in
Table 3. The amplified products were separated by electrophoresis in
1 % agarose gels and stained with ethidium bromide. DNA ladder
(ReadyLoad 100 bp, Invitrogen) was used as a molecular mass
marker to indicate the sizes of the amplified products.
RESULTS AND DISCUSSION
The type strains of C. botulinum type C and D, 4564 (NCTC
373) and 3923 (NCTC 8265), respectively, were the only-
strains in which the genes for the C and D neurotoxins were
detected (Fig. la). These also carried the genes for both
components of the C2 toxin (Fig. lb), but note the size of
the PCR product for the type D strain was larger than for
that found in the type C or C. novyi strains. However,
sequencing and a BLAST search identified it as the gene for C2
component I (results not shown). Two strains originally
supplied by NCTC as type C cultures 2510 (NCTC 10914)
and 4565 (NCTC 3732) had previously been shown to be
BoNT/C-negative by use of a specific ELISA for the toxin
and this was confirmed by PCR. Both of the neurotoxin-
producing strains also yielded the expected amplification
products for both genes of the components of C2 toxin, as
did one of the BoNT/C-negative strains. However, the other,
4565, yielded the C2 component I gene but not component
II. The loss of the neurotoxins has been acknowledged by
NCTC.
Of the 40 strains originally named as C. novyi type A or C.
novyi type A-like, only 22 (55 %) tested positive for the C.
novyi a toxin gene by PCR. All negative strains were tested
on at least two further occasions with consistently negative
results for the a toxin gene. Whether this result is real or due
to sequence mismatch at the site ofprimers is not yet known.
Further work involving sequence determination of several
different x toxin genes and the design of new primers would
clarify this point. Unexpectedly, however, 28 of the C. novyi
strains (77%) contained the gene for the C2CI toxin (these
included 16 of the 22 a toxin-positive strains). Five 'C. novyi
strains (12.5%) contained the gene for the C2CII toxin
(three a toxin-positive and two negative) and nine (22.5%)
were negative for both components. No a toxin-positive
isolates contained both of the C2 components. The overall
distribution of gene profiles is indicated in Table 1 and is
summarized in Table 4.
As far as we can ascertain few, if any, of the so-called C. novyi
strains had been tested in our laboratory specifically for the x
toxin when originally identified, although some guinea pig
inoculations had been performed in the 1970s but records
are sketchy. However, all gave biochemical profiles -
including volatile fatty acid patterns typical of C. novyi
type A, but the gene encoding the a toxin was detected in
only just over half of our collection.
It is noteworthy that all of the strains in our collection that
had been isolated from cases of infection in IDUs, with
characteristic pathology, were found to contain the gene for
the a toxin. In 2000 there were 60 cases of extremely serious
infection in Scotland with 23 deaths, with C. novyi definitely
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Table 1. List of clostridial strains used and toxins identified
Lab no. Original identity Source Toxin profile (CI D C2I C2II a)*
141 C. novyi type A-like Horse ileum, subacute EGS +
465 C. novyi type A Wound site, common bile duct drain +
2306 C. novyi type A ? +
2307 C. novyi type A ? + + -
2510 C. botulinum type Ct NCTC 3732 + + -
2530 C. novyi type A NCTC 538 + - +
2531 C. novyi type A Glaxo collection + - +
2533 C. novyi type A NCTC 6735 +
2534 C. novyi type A ? + + -
2535 C. novyi type A ? +
2536 C. novyi type A ? + - +
3209 C. novyi type A PHLS 2680 + - +
3341 C. novyi type A Soil (St Kilda)
3923 C. botulinum type D NCTC 8265 - + + + -
4540 C. novyi type A Injection site (Glasgow) + - +
4541 C. novyi type A Injection site (Glasgow) + - +
4545 C. novyi type A Crush injury wound swab + - +
4547 C. novyi type A Injection site (PHLS Cardiff) + - +
4548 C. novyi type A Injection site (PHLS Cardiff) + - +
4549 C. novyi type A Horse ileum, AGS +
4550 C. novyi type A Horse ileum, AGS
4551 C. novyi type A Horse ileum, AGS h
4552 C. novyi type A Hare with dysautonomia, small intestine - +
4553 C. novyi type A Hare with dysautonomia, small intestine
4554 C. novyi type A Hare with dysautonomia, small intestine +
4556 C. novyi type A Horse faeces, CGS
4557 C. novyi type A Horse faeces, recovered CGS
4558 C. novyi type A Horse faeces, contact CGS +
4559 C. novyi type A Horse faeces, contact CGS
4561 C. novyi type A Horse ileum, AGS +
4562 C. novyi type A Horse ileum, CGS + - +
4563 C. novyi type A Horse faeces, CGS h - +
4564 C. botulinum type C NCTC 8548 + - + + -
4565 C. botulinum type Ct NCTC 10914 +
4566 C. novyi type A Injection site (Glasgow) + - +
4567 C. novyi type A Injection site (Glasgow) + - +
4568 C. novyi type A NCTC 6738 + - +
4569 C. novyi type A Injection site (Dublin) + - +
4570 C. novyi type A ARU collection - +
4571 C. novyi type A NCTC 538 + - +
4572 C. novyi type A Injection site (Bournemouth) - +
4573 C. novyi type A Injection site (Glasgow) + +
4574 C. novyi type A Injection site (Glasgow) + +
4575 C. novyi type A Injection site (Stockton) _ _ _ + +
EGS, Equine grass sickness; AGS, acute form of EGS; CGS, chronic form of EGS; PHSL, public health service laboratory; ARU, Anaerobe
Reference Unit at Cardiff; ?, source unknown.
"Toxin profile: CI, BoNT/C; D, BoNT/D; C2I, C2 component I; C2II, C2 component II; 2, C. novyi i toxin; +, positive; —, negative.
fNon-neurotoxin producer.
implicated in 23 cases and probably implicated in 37 cases as
the cause. Spores ofClostridia can contaminate the materials
used by IDUs and when introduced into tissue in an
anaerobic environment the spores can germinate and
produce exotoxins. All of the cases in Scotland involved
IDUs injecting a solution ofstreet heroin and citric acid into
muscle tissue (McGuigan et al., 2002). The few samples of
heroin cultured from this outbreak were negative for C.
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Table 2. Primer sequences used for the detection of C. botulinum types C and D, C. novyi oc and C2 components
Gene Primer Sequence Reference
Type C neurotoxin Tox-384 5' -AAACCTCCTCGAG'ITACAAGCCC-3' Williamson el al. (1999)
Tox-850 5' -C.AAAATCTACCCTCTCCTACATCA - 3'
Type D neurotoxin ToxD-F 5' -GTGATCCTGTTAATGACAATG -3' Sunagawa et al. (1992)
ToxD-R 5' -TCCTTGCAATGTAAGGGATGC-3'
C. novyi x toxin Nov-F 5'-GGTGCGATTCAAGAGGCCACA-3' Hofmann et al. (1995)
Nov-R 5' -CGCTCCTAGCAGTCCCGAAAT-3'
C2 component I C2CI-F 5'-AAGGAAGATAAAACAAAAAT-3' Fujii et al. (1996)
C2CI-R 5' ■-CCTAATGATACAAATGAAAA- 3'
C2 component II C2CII-F 5' -GCAGAAGTTTCAGGTAGrrTACAAC-3' Based on sequence
C2CII-R 5' -CGCATTCTATAACGACCTTCTGGA-3' Kimura et al. (1998)
novyi (Jones et al., 2002) but the circumstantial evidence was
compelling that C. novyi type A was the main if not only
agent involved in the majority of cases.
The isolates obtained from environmental and animal
sources do not appear to have the same distribution of toxin
genes. Only 3/14 of these animal isolates contained the a
toxin gene though all were phenotypically similar.
None of the isolates obtained from IDUs contained both
components of the C2 toxin, but the majority (62%)
contain only the gene for the enzymic component (C2CI). It
is possible that the C2C1I transport component is not
needed for transport into an already-damaged cell with the
active C2CI component alone contributing to the pathol¬
ogy. The animal and environmental isolates show a similar
pattern with 43 % containing the enzyme component of the
C2 toxin and no isolates containing the gene for the binding
component. None of the strains in our collection contained
both of the C2 component genes together with the a toxin
genes. In fact the only strains containing genes for both
components of C2 were the two type strains of neurotoxin
producing C. botulinum (C and D) together with one of the
BoNT/C-negative strains, and two C. novyi strains in which
the a toxin genes were not detected (strains 2307 and 2534).
Unfortunately the origin of these strains was not recorded
but they could well represent C. botulinum strains that had
lost their toxin-encoding phages.
Of the six strains in which none of the toxin genes was
detected, one was from soil, and the others were from the
gastrointestinal tracts of a hare with dysautonomia and four
horses (two with active dysautonomia).
It is evident that the complement of toxin genes that is
carried by isolates of this group of Clostridia is extremely
variable. To cause classical botulism, the specific neurotox¬
ins must be produced. Similarly, typical clinical C. novyi-
mediated disease almost certainly requires the a toxin to be
produced to induce the classical oedematous lesions.
However, depending on the type of clinical situation, it is
possible that the C2 toxin alone, or in combination with a
Table 3. Cycling conditions used for the detection of C. botulinum types C and D, C. novyi a and C2 components
Primer Initial denaturation No. of cycles Cycling condition Final extension
Tox-384/Tox850 5 min at 80 C 30 1 min at 95 C
1 min at 55 C
1 min at 72 C
5 min at 72 ' C
ToxD-F/ToxD-R 10 min at 95 C 25 1 min at 94 ~C
1 min at 55 C
1 min at 72 C
3 min at 72 C
Nov-F/Nov-R 3 min at 94 C 30 1 min at 95 C
1 min at 48 C
1 min at 72 C
5 min at 72 C
C2C1-F/C2CI-R 3 min at 94 C 35 45 s at 94 C
2 min at 45 C
1 min at 72 C
5 min at 72 C
C2CII-F/C2CII-R 3 min at 94 C 40 45 s at 94 C
1 min at 53 C
3 min at 72 1 C
5 min at 72 C
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(a) Table 4. Distribution of toxin genes in Group III Clostridia







Fig. 1. (a) PCR for the genes encoding the two neurotoxins
and C. novyi a toxin. Lanes 1 and 2, BoNT/C, strain 4564 and
negative control; lanes 3 and 4, BoNT/D, strain 3923 and
negative control; lanes 5 and 6, C. novyi a toxin, strain 2307
and negative control. Side lanes 100 bp DNA ladder, (b) PCR
investigating the same three strains as in (a) for the genes
encoding the two components of the C2 toxin. C2CI, lanes
1-4, strains 4564, 3923, 2307 and negative control; C2CII,
lanes 5-8, strains 4564, 3923, 2307 and negative control.
Note that the PCR product for the C. botulinum type D strain
is larger than the C. botulinum type C and C. novyi type A
strains.
toxin or neurotoxin, may contribute towards the pathology.
If x toxin is present there does not seem to be a major
requirement for the C2CII component. However, when in
combination with the botulinum neurotoxin it seems that
both components may be required.
As the various toxins - both neurotoxins and lethal toxins -
are likely to affect the pathogenic potential of individual
strains it is useful to know which ones they produce.
However, this may be difficult because of the inherent
instability of the pseudolysogenic bacteriophages that
encode the two neurotoxins and the a toxin. In nature
this does not matter as constant cycles of loss and
reacquisition of the bacteriophages will presumably occur.
Additionally, the process of sporulation may result in the
bacteriophage being lost from the cell. It is therefore
important to try to prevent loss during the initial isolation
and early subculture of toxigenic strains. It is recommended
that several colonies are selected and they are cultured in
liquid medium to allow the infection-reinfection to take
place and thereby prevent this.
In conclusion, this preliminary investigation by PCR - using
previously published sequences for all but the C2 component
Profile of toxin genes Number
C. novyi c< + , C2CI + , C2CII + 0
C. novyi a + , C2CI + , C2CII" 16
C. novyi a + , C2CI~, C2CII~ 3
C. novyi a+ , C2CI", C2CII + 3
C. novyi a", C2CI"*", C2CII + 5*
C. novyi a-, C2CI + , C2CIP lit
C. novyi a~, C2CI", C2CII" 6
^Includes two C. botulinum type C (one BoNT/C + and one BoNT/
C—) and one C. botulinum type D (BoNT/D+ ).
tlncludes one C. botulinum type C (BoNT/C—).
II gene - has shown the variety of combinations of toxin
genes found in this group of related Clostridia. The detection
of at least one of the genes encoding the components of the
C2 toxin in strains that appear to be C. novyi is novel and
suggests a role for one or both of the components in the
pathogenesis of these organisms. The failure to detect
certain genes - especially the a toxin genes in strains
previously identified as C. novyi - may be real, or could be
due to polymorphisms in the genes for these toxins with the
primers we have selected not matching adequately. This
must be investigated in any future studies.
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